Abrocitinib (PF-04965842)
B7451061Final Protocol, [ADDRESS_1205097] OF 
AN ACID-REDUCING AGENT ON THE BIOAVAILABILITY OF ABROCITINIB
COMMERCIAL TABLET AND TO ASSESS THE TASTE OF ABROCITINIB ORAL 
FORMULATIONS IN HEALTHY ADULT PARTICIPANTS AGED 18 TO 55 YEARS
OF AGE
Study Intervention Number: PF-04965842
Study Intervention Name: [CONTACT_864320]:EudraCT Number: N/A
Protocol Number: B7451061
Phase: 1
Brief Title: A Phase [ADDRESS_1205098] of an Acid-Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations in Healthy Adult Participants Aged 18 to 55 Years of Age.
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCI
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Original protocol 06May 2021

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205099] OF FIGURES ...................................................................................................................8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................14
1.3. Schedule of Activ ities .............................................................................................15
2. INTRODUCTION ...............................................................................................................20
2.1. Study  Rationale .......................................................................................................20
2.2. Background .............................................................................................................20
2.2.1. Mechanism of Action/I ndication ................................................................20
2.2.2. Overview of Disease S tate..........................................................................21
2.2.3. Rationale for Development of Abrocitinib
.................................................21
2.2.4. Nonclinical Pharmacology ..........................................................................22
2.2.5. Nonclinical Pharmacokinetics and Metabolism .........................................23
2.2.6. Nonclinical Safet y
......................................................................................23
2.2.7. Clinical Overview .......................................................................................24
[IP_ADDRESS]. Summary  of Safety  Data from Completed Studies ...................24
[IP_ADDRESS]. Summary  of Abrocitinib Pharmacokinetics, Metabolism 
and In Vitro Enzy mology ..................................................................26
2.3. Benefit/Risk Assessment
.........................................................................................28
3. OBJECTI
VES AND EN DPOINTS .....................................................................................29
4. STUDY DESIGN .................................................................................................................29
4.1. Overall Design .........................................................................................................29
4.2. Scientific Rationale for Study  Design .....................................................................32
4.2.1. Choice of Contraception/Barrier Requirements .........................................34
4.2.2. Collection of Retained Research Samples ................................ .................. 34
4.3. Justification for Dose ..............................................................................................34
4.4. End of Study  Definition ..........................................................................................35
5. STUDY POPUL ATION
................................ ................................ ................................ ......35
5.1. I nclusion Criteria .....................................................................................................35
5.2. Exclu sion Criteria ....................................................................................................37

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 45.3. L ifesty le Considerations ..........................................................................................40
5.3.1. Meals and Dietary  Restrictions ...................................................................40
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................40
5.3.3. Activity .......................................................................................................40
5.3.4. Contraception ..............................................................................................41
5.4. Screen Failures ........................................................................................................41
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................41
6.1. Study  Intervention(s) Administered ........................................................................41
6.1.1. Administration ............................................................................................44
6.2. Preparation, Handling, Storage, and Accountability ...............................................44
6.2.1. Preparation and Dispensing ........................................................................45
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................46
6.3.1. Allocation to Study Intervention ................................................................46
6.4. Study  Intervention Compliance ...............................................................................46
6.5. Dose Modification ...................................................................................................46
6.6. Continued Access to Study  Intervention After the End of the Study ......................46
6.7. Treatment of Overdose
............................................................................................46
6.8. Concomitant Therapy ..............................................................................................47
6.8.1. Rescue Medicine .........................................................................................48
7. DI SCONTINUATION OF STUDY INTERVENTI ON AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................48
7.1. Discontinuation of Study  Intervention ....................................................................48
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_1205100] to Follow -up ....................................................................................................49
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................49
8.1. Efficacy  Assessments ..............................................................................................51
8.2. Safet y Assessments .................................................................................................51
8.2.1. Physical Examinations ................................................................................51
8.2.2. Vital Signs ..................................................................................................51
[IP_ADDRESS]. Temperature ..............................................................................52
8.2.3. Electrocardiograms
.....................................................................................52

Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 58.2.4. Clinical Safety La boratory Asse ssments ....................................................53
8.2.5. COVID-19 Specific Assessments...............................................................538.2.6. Pregnancy Testing ......................................................................................53
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................54
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......54
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the DCT ..................55
8.3.2. Method of Detecting AEs and SAEs ..........................................................558.3.3. Follow-Up of AEs and SAEs......................................................................558.3.4. Regulatory Reporting Requirements for SAEs...........................................568.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................56
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................58
8.3.6. Cardiovascular and Death Events...............................................................588.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_1205101].............................................................59
[IP_ADDRESS]. Lack of Efficacy........................................................................59
8.3.9. Medical Device Deficiencies......................................................................598.3.10. Medication Errors .....................................................................................59
8.4. Pharmacokinetics ....................................................................................................60
8.4.1. Plasma for Analysis of Abrocitinib and Metabolites..................................60
8.6. Biomarkers ..............................................................................................................62
8.7. Immunogenicity Assessments .................................................................................628.8. Health Economics ...................................................................................................62
9. STATISTICAL C ONSIDERATIONS ................................................................................62
9.1. Statistical Hypotheses .............................................................................................62
9.2. Analysis Sets ...........................................................................................................63
CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 69.3. Statistical Analyses .................................................................................................63
9.3.1. Safety Analys es ..........................................................................................63
[IP_ADDRESS]. Electrocardiogram Analyses......................................................64
9.4. Interim Analyses .....................................................................................................66
10. SUPPORTING DOCUMENTS AND OPERATIONAL CONSIDERATIONS...............68
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............68
10.1.1. Regulatory and Ethical Considerations ....................................................68
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................69
10.1.2. Informed Consent Process ........................................................................6910.1.3. Data Protection .........................................................................................7010.1.4. Committees Structure ...............................................................................70
[IP_ADDRESS]. Data Monitoring Committee ...................................................70
10.1.5. Dissemination of Clinical Study Data ......................................................7110.1.6. Data Qualit y Assurance ............................................................................72
10.1.7. Source Documents....................................................................................7310.1.8. Study and Site Start and Closure ..............................................................7310.1.9. Publication Policy.....................................................................................7410.1.10. Sponsor’s Qualified Medical Personnel .................................................75
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7610.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................79
10.3.1. Definition of AE .......................................................................................7910.3.2. Definition of an SAE ................................................................................8010.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................81
10.3.4. Reporting of SAEs....................................................................................85
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................86
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................86CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 710.4.2. Female Participant Reproductive Inclusion Criteria.................................86
10.4.3. Woman of Childbearing Potential ............................................................8610.4.4. Contraception Methods.............................................................................87
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......90
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................9210.8. Appendix 8: Taste Assessment Questionnaire......................................................9410.9. Appendix 9: Abbreviations .................................................................................103
11. REFERENCES ................................................................................................................1 07CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, [ADDRESS_1205102] OF TABLES
Table 1. Schedule of Activities (Part A)................................................................15Table 2. Schedule of Activities (Part B) .................................................................17
Table 4. Randomized Treatment Sequences of Part A ...........................................30
Table 5. Randomized Treatment Sequences of Part B ...........................................31Table 6. Summary of Abrocitinib Oral Suspension Formulations to be 
administered for PK and Taste Assessment..............................................43
Table 7. Safety QTc Assessment ............................................................................64Table 8. Derivation of PK Parameters....................................................................65Table 9. Width of 90% CIs for Different Estimated Effects of 
Test/Reference Ratio ................................................................................66
Table 10. Half width of a two-sided 90% CI of the estimated mean for each of 
the taste assessment questions, with 80% coverage probability...............[ADDRESS_1205103] OF FIGURES
Figure 1. Abrocitinib pH Solubility Curve ..............................................................34CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 91. PROTOCOL SUMMARY 
1.1. Synopsis Brief Title: A Phase [ADDRESS_1205104] of an Acid-Reducing Agent on the Bioavailability of Abrocitinib andAssessing the Taste of Abrocitinib Oral Formulations in Healthy Adult Participants Aged 18 to 55 Years of Age.
RationalePF-04965842 (abrocitinib) is a JAK 1 inhibitor that is developed for the treatment of AD. 
Key cytokines implicated in the pathophysiology of AD including IL-4, IL-5, IL-13, IL-22, 
IL-31, and IFN- γ, require JAK1 for signal transduction, suggesting that selective JAK1 
inhibitors, that modulate the activity of these cytokines, represent a compelling approach to the treatment of inflammatory skin diseases such as AD. Abrocitinib is being developed as an oral treatment for participants with moderate to severe AD based on its mechanism of action, and the clinical results obtained in Phase 1 and Phase 2 studies.
Abrocitinib pediatric program will be initiated to fulfill the regulatory requirements. Critical 
to the regulatory requirements is the development and filing of a pediatric age-appropriate formulation for AD participants aged 6 months to <12 years, with rBA similar to currently developed abrocitinib commercial tablet and with acceptable palatability. Thus, this study will be conducted to estimate the rBA of an oral suspension formulation of abrocitinib compared to abrocitinib commercial tablet. The potential effects of alterations in gastrointestinal pH induced by [CONTACT_864302]. A taste evaluation will also be conducted to assess the taste and palatability of six different oral suspension formulations for abrocitinib. The results of this taste assessment will help in guiding the selection and development of abrocitinib pediatrics formulation and inform whether taste masking is required for the commercial pediatric formulation.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 10 
As described above, this study consists of 2 parts: Part A is to estimate the rBA of a single 
200 mg dose of abrocitinib oral suspension compared to the commercial abrocitinib tablet (200 mg). The effect of ARA on the BA of abrocitinib and its metabolites will also beevaluated by [CONTACT_864303] 200 mg commercial tablet with or without famotidine 40 mg, as an ARA. Part B is to assess the taste and palatability of six different abrocitinib oral suspension formulations, to guide the selection and development of abrocitinib pediatrics formulation.  
CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 11Objectives and Endpoints
Objectives Endpoints
Primary: Primary: 
Part A:
•Estimate the rBA of abrocitinib 200 mg oral 
suspension formulation 1 compared to the 
1×200 mg of abrocitinib commercial tablet under fasting condition.
•Evaluate the effect of a single dose of an acid-
reducing agent (famotidine 40 mg) on the BAof abrocitinib 1×200 mg commercial tablet under fasting conditions.•Plasma abrocitinib PK parameters: AUC
inf(if 
data permit), AUC lastand C maxafter 
administration of abrocitinib oral suspension formulation and commercial tablet.
•Plasma abrocitinib PK parameters: AUC
inf (if 
data permit), AUC lastand C maxafter 
administration of ARA plus abrocitinib commercial tablet.
Part B:
•Evaluate the taste and palatability of 
6 abrocitinib suspension formulations using a 200 mg dose.•Taste Assessment Survey Scoring Metrics after 
suspension formulation: mouthfeel, bitterness, tongue/mouth burn, saltiness, sourness, and overall liking.
Secondary: Secondary: 
 
 
•Determine the PK of metabolites (M1, M2 and 
M4) following the administration of 1×200 mg of abrocitinib commercial tablet with or withoutan ARA (famotidine 40 mg) in Part A.
•Evaluate the safety and tolerability following 
oral administration of each of the abrocitinib formulations in Parts A and B.•PK parameters: AUC
inf(if data permit), AUC last
and C maxafter administration of 1×200 mg of
abrocitinib commercial tablet with or without an ARA.
•Assessment of TEAEs, clinical laboratory tests, 
vital signs, and 12-lead ECGs.
 
 
 
 CCIC
CIC
C
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 12Overall Design
Brief Summary
This is a Phase 1 randomized, crossover study  in healthy  participants to estimate the rBA of 
abrocitinib oral suspension (Test formulation) compared to commercial abrocitinib tablet
(Reference formulation) under fasted condition. The effect of ARA on the BAof the 
commercial tablet formulation will be evaluated by [CONTACT_864303] 200 mg 
commercial tablet with famotidine 40 mg as an ARA . Assessment of taste and palatability  of 
six different abrocitinib suspensions will also be performed to guide the selection and 
development of abrocitini
bpediatric s oral suspension formulation. This study  consists of 
2parts, as listed below.
Part A: 
Part A of the stud y will be an open label, randomized, single dose, crossover, 3 -treatment, 
6 -sequence, 3- period design in healthy  male and/or female adult participants (18 -55 years). 
Health y participants will be screened within [ADDRESS_1205105] administration of the 
study  intervention to confirm that they  meet the participant selection criteria for the study . 
Eligible participants will be admitted to the CRU on Day -1and will be confined in the CRU 
until discharge, on Day 2of Period 9in Part B, after completing both Parts A and B of the 
study .In Part A, p articipants will be randomized to receive one of the following: a single 
200mg dose of abrocitinib commercial tablet (Treatment A) ,a single 200 mg dose of 
abrocitinib oral suspension formulation 1 (Treatment B) , orfamotidine (40 mg) administered 
120 minutes before a single 200 mg dose of abrocitinib commercial tablet (Treatment C) . All 
participants will befasting for at least 10 hours before taking abrocitinib.
Part B: 
Participants who complete Part A of the stud y are expected to proceed to PartB. Part B will 
be a single -blind, randomized, 6- period, crossover study  in health y male and/or female adult 
participants (18 -55 years). For any new healthy  participants joining Part B only to support 
the achievement of the required number of health y participants enrolled and randomized in 
this part of the study , screening will be performed within [ADDRESS_1205106] 
administration of the study  intervention to confirm that they  meet the participant selection 
criteria for the stud y. New participants enrolled in Part B only will be admitted to the CRU 
on Day  -1 and will be confined in the CRU until discharge, which is Day 2of Period 9. On 
Day 1 of each treatment period under fasted conditions, participants will receive a famotidine 
tablet (40 mg with 240 mL of room temperature water) administered 120 minutes before a 
single 200 mg dose of abrocitinib oral suspensions ( Formulations 1 to 6 ) or administered a 
single 200 mg dose of abrocitinib oral suspension alone ( Formulations 1 to 6), after a fast of 
at least 10 hours before abrocitinib administration. 
Number of Participants
In Part sA and B of the study , approximately  18 participants will be randomly  assigned t o 
study  intervention (1 of 6 sequences).

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 13Intervention Groups and Duration
Part A:
Each randomized treatment sequence will consist of 3 treatment periods.
Randomized Treatment Sequences of Part A
Sequence Period 1 Period 2 Period 3
1 (n=3) A B C
2 (n=3) B C A
3 (n=3) C A B
4 (n=3) A C B
5 (n=3) B A C
6 (n=3) C B A
Treatment A = Abrocitinib 200 mg commercial tablet only ,under fasted conditions.
Treatment B = Abrocitinib 200 mg o ral suspension formulation 1 only,under fasted conditions.
Treatment C = Famotidine 40 mg tablet administered 2 hours prior to abrocitinib 200 mg commercial tablet 
under fasted conditions.
Part B:
Each randomized treatment sequence will consist of 6 treatment periods.
Randomized Treatment Sequences of Part B
Sequence Period 4 Period 5 Period 6 Period 7 Period 8 Period 9
1 (n=3) F1+ARA F2+ARA F3+ARA F4+ARA F5+ARA F6+ARA
2 (n=3) F6+ARA F1+ARA F2+ARA F3+ARA F4+ARA F5+ARA
3 (n=3) F5+ARA F6+ARA F1+ARA F2+ARA F3+ARA F4+ARA
4 (n=3) F4 F5 F6 F1 F2 F3
5 (n=3) F3 F4 F5 F6 F1 F2
6 (n=3) F2 F3 F4 F5 F6 F1
F1 = Abrocitinib oral suspension formulation 1 under fasted conditions.
F2 = Abrocitinib oral suspension formulation 2 under fasted conditions.
F3 = Abrocitinib oral suspension formulation 3 under fasted conditions.
F4 = Abrocitinib oral suspension formulation 4 under fasted conditions.
F5 = Abrocitinib oral suspension formulation 5 under fasted conditions.
F6 = Abrocitinib oral suspension formulation 6 under fasted conditions.
ARA = Famotidine 40 mg under fasted condition.
Abrocitinib oral suspension f ormulations 1 to 6for tasting will be offered to all participants 
in a blinded fashion. Participants randomized to Sequence 1-3 will receive famotidine (40 mg 
with 240 mL  of room temperature water) [ADDRESS_1205107] samples into their mouths, swish 
the sample in the mouth for approximately  10 seconds and then swallow it. Each participant 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205108] the sensory  attributes at timed intervals of 0 (immediatel y after dosing), 5, 10, and 
[ADDRESS_1205109] is approximately  10weeks. Participants who discontinue the study  may  be 
replaced at the sponsor’s discretion. The replacement participant will receive the same 
treatment sequences as the participant who discontinued.
Data Monitoring Committee or Other Independent Oversight Committee : No
Statistical Methods
For the rBA portion of Part A , natural log -transformed PK parameters (AUC inf, AUC last, and 
Cmax) will be analy zed using a mixed
-effect model with sequence, period and treatment as 
fixed effects and participant within sequence as a random effect. For PartB, the data used in 
the anal ysis will be transcribed and rescaled to a score from 0 to 100 from the raw 
measurements on the questionnaire. The sensory  attributes (overall liking, mouthfeel, 
bitterness, sourness, saltiness, tongue/mouth burn) from the taste questionnaires will be listed 
and descriptivel y summarized by  [CONTACT_864304], and question across participants. 
1.2.Schema
Not applicable.

Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 151.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evalua tions or 
assessments required to protect the well-being of the participant.
Table 1. Schedule of Activities (Part A)
Visit Identifiera
Abbreviations used in this table may be found in 
Appendix 9: AbbreviationsScreeningbPeriod 1 Periods 2 Period 3 Early Termination/
DC
Days Relative to Day 1 Day -28 to
Day -2Day -1 Day 
1Day 
2Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3c
Informed consent X
CRU confinement X →→→→→→→→ → X
Inclusion/exclusion criteria X X
Medical, drug, tobacco and alcohol history X X
Physical examinationdXX X X
Height and weight assessment X
Safety laborator yeXX X
Demography (including height and weight) X
Pregnancy test for WOCBP only X X X
Contraception check for WOCBP onl y XX X
Serum FSH in post-menopausal femalesfX
Urine drug testing X X
Single 12-Lead ECG X XgX
Supi[INVESTIGATOR_30991], pulse rate, and oral temperature X XhX
Serology: HBcAb, HBsAg, HBsAb, HCVAb, HIV 
testsiX
QuantiFERON®- TB Gold TestjX
COVID-19 questionnairekXX
COVID-19 testinglXX X
COVID-19 check temperaturemX X X XXXXXXX X
Study treatment administrationnX X X
CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 16Table 1. Schedule of Activities (Part A)
Visit Identifiera
Abbreviations used in this table may be found in 
Appendix 9: AbbreviationsScreeningbPeriod 1 Periods 2 Period 3 Early Termination/
DC
Days Relative to Day 1 Day -28 to
Day -2Day -1 Day 
1Day 
2Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3c
CRU discharge X
Serious and nonserious AE monitoring X X →→→→→→→→ → →
Prior/concomitant treatments X X →→→→→→→→ → →
a. Day relative to the first day of study intervention dosing in all periods.
b. Screening must take place a maximum of 28 days prior to the administration of the study intervention in Period 1.c. Day 3 of Period 3 in Part A of the study overlaps with Day -1 of Period 4 in Part B of the study.
d. A complete physical examination will be done at screening or may be deferred to Day -1 of Period 1 at the discretion of the in vestigator. A complete physical examination 
would also be performed at the Early Termination/DC visit (if this occurs). A brief physical examination would be performed at D ay 3 of Period 3 and could be performed at 
other times if findings during the previous examination or new/open AE, at the discretion of the investigator.
e. Safety laboratory assessments must be collected following at least a 4-hour fasting. For details on the tests to be performed,  please refer to protocol Appendix 2 . The 
hematology, urinalysis, and clinical chemistry tests will be performed at screening, each admission to the CRU, at Day -1 of Peri od 4 in Part B, at study discharge, and early 
withdrawal. Samples will be collected if the reason for DC is related to an AE. Additional assessments may be performed at the d iscretion of the investigator.
f. Females who are amenorrheic ≥12 consecutive months only.
g. To be collected at predose of abrocitinib.
h. To be collected at predose and 1-hour postdose (around T
max) of abrocitinib.
i. HBsAb tested as reflex test only in participants who are HBsAg negative but are HBcAb positive.j. QuantiFERON test to be performed at screening. Prior QuantiFERON test is acceptable when performed within the [ADDRESS_1205110] 
will be performed after 4 days (ie, upon completion of 4 × 24 hours in-house), or if they develop COVID-19 like symptom(s).
m. To be done at least daily during residence. n. As per assigned randomization and treatment schedule. Study intervention administration should be separated by a period of at least 72 hours (washout). 
 C
CICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 17Table 2. Schedule of Activities (Part B)
Visit Identifiera
Abbreviations used in this table may be 
found in Appendix 9: AbbreviationsPeriod 4 Period 5 Period 6 Period 7 Period 8 Period 9 Early Termination/
DCFollow-upb
Days Relative to Day 1 Day -1cDay 1 Day 1 Day 1 Day 1 Day 1 Day 1 Day 2 28-35 Days
Informed consentd
CRU confinement → →→ → → → → XX
Inclusion/exclusion criteriad
Physical examinationeXX
Safety laboratoryfXX X
Pregnancy test for WOCBP only XX
Contraception check for WOCBP onl y XX X X
Single 12-Lead ECG XgXX
Supi[INVESTIGATOR_30991], pulse rate, and oral 
temperatureXXhXX
COVID-19 testing Xi
COVID-19 check temperaturejX X XXXX X
Study treatment administration X X X X X X
Taste Assessment QuestionnairekX XXXX X
 
CRU discharge XX
Serious and nonserious AE monitoring  →→ → → → → →  → X
Prior/concomitant treatments  →→ → → → → →  → XCCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 18Table 2. Schedule of Activities (Part B)
Visit Identifiera
Abbreviations used in this table may be 
found in Appendix 9: AbbreviationsPeriod 4 Period 5 Period 6 Period 7 Period 8 Period 9 Early Termination/
DCFollow-upb
Days Relative to Day [ADDRESS_1205111] occur 28 to 35 days from administration of the final dose of study interventi on, either in Parts A (in case of early 
termination/DC) or in Part B of the study
c. Day -1 of Period 4 in Part B of the study overlaps with Day 3 of Period 3 in Part A of the study.
d. For new participants enrolled in Part B only, all Screening and Day -1 visit procedures will be performed as listed in Table 1 SoA (Part A).
e. A complete physical examination will be done at screening or may be deferred to Day -1 of Period 4 at the discretion of the in vestigator for new participants admitting for 
Part B only of the study.  A complete physical examination should be performed on Day 2 of Period 9 or at the Early Termination /DC visit (if this occurs). A brief physical 
examination can be performed at other times if findings during the previous examination or new/open AE, at the discretion of th e investigator.
f. Section 8.2.[ADDRESS_1205112] a 4-hour fasting period. Samples will be collected if the reason for DC is related to an AE. Addit ional assessments may be performed at the 
discretion of the investigator. 
g. To be collected at predose of abrocitinib for new participants enrolled in Part B only.
h. To be collected at predose and 1-hour postdose (around T max) of abrocitinib.
i. For new participants joining this part of the study, and admitted for residence, a subsequent COVID-[ADDRESS_1205113] will be performed after 4 days (ie, upon completion of 4 × 24 
hours in-house), or if they develop COVID-19 like symptom(s).
j. To be done at least daily during residence. 
k. Review taste questionnaire and instructions with participants prior to the first taste assessment on Period 4, Day 1. Each pa rticipant will record the sensory attributes at timed 
intervals of 0 (immediately after dosing), 5, [ADDRESS_1205114] ionnaire (see Appendix 8 ). 
 
 
 C
CI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 19  
 CCI
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 202.INTRODUCTION
Abrocitinib (also referred to as PF-04965842) is an orally  bioavailable potent JAK1 inhibitor
with good selectivity  over the broader kinome being developed for the treatment of AD.[ADDRESS_1205115] ion/Indication
The JAK family , including JAK1, JAK2, JAK3 and TYK2, is a group of cy toplasmic 
tyrosine kinases that mediates signal transduction via interactions with Ty pe1 and Ty pe 2 
cytokine receptors critical for leukocy te activation, proliferation, survival and function. 
Cytokine receptors demonstrate restricted association with JAKs such that different receptors 
or receptor classes preferentially utilize a given JAK dimer or trimer combination to 
transduce their signal.1JAK1 pairs with JAK3 to mediate γ- common cy tokine signaling and 
also with JAK2 or TYK2 to transmit the signals of additional cy tokines important in 
inflammation and immune responses including IL-4, -5, -6, -13, -21, -31, TSLP,IFN-γ, and 
IFN-α. JAK2 homodimers are critical for the signaling of hematopoietic cy tokines and 
hormones including ery thropoietin, IL -3, granulocy te-macrophage colony -stimulating factor 
and prolactin. IL
-12 and IL -23 are de pendent on TYK2 and JAK2 for transmitting their 
signals.1
Following cy tokine activation, receptor -associated JAKs are phosphory lated, and in turn 
phosphory late spe cific sites on the receptor intracellular domain. Phosphorylation of specific 
sites on the intracellular domain of the receptor allows for the recruitment of STATs that can 
subsequently  be phosphory lated by  [CONTACT_74061].2Phosphory lated STAT molecules are released
from the receptor, translocate to the nucleus where they  bind to specific sites on the DNA 
and regulate gene transcription.3
Key cytokines implicated in the pathophy siology of AD including IL-4,IL-5,IL-13,IL-22,
IL-
31,and IFN-,require JAK1 for signal transduction ,suggest ingthat selective JAK1 
inhibitors, that modulate the activity of these cytokines ,represent a compelling approach to 
the treatment of inflammatory skin diseases such as AD .[ADDRESS_1205116] other 
kinases: 28- fold selectivity  over JAK2, >[ADDRESS_1205117] s involved in the 
pathophy siology  of AD, including IL -4, IL -13, IL -31 and IFN -. Data from a Phase 2b POC 
study  (B7451006) 
that evaluated participants with moderate to severe AD have shown 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205118] 50 years, AD has become more prevalent, especiall y in industrialized, 
temperat e countries such as the US .5,6Earlier reports indicated that, in up to 70% of cases, 
the disease greatl y improves or resolves until late childhood, however more recent findings 
suggest that disease activity  remains manifest for a prolonged period of time. Based on a total 
of [ADDRESS_1205119] well into the second 
decade of a child’s life and likely longer. At every age, more than 80% of PEER study
participants hadsymptoms of AD and/or were using medication to treat their AD.
There area limited number of treatments available for AD. Current treatments for AD 
include emollients, topi[INVESTIGATOR_11930] (eg, betamethasone, clobetasol, fluocinonide), 
topi[INVESTIGATOR_22726] (eg, pi[INVESTIGATOR_031], tacrolimus), and coal tar preparations.
Crisaborole was approved as a topi[INVESTIGATOR_74019] 2016 by  [CONTACT_864305]. In addition, d upi[INVESTIGATOR_12458], an injectable mo noclonal 
antibody  targeting IL-4 and IL-13 was approved for the treatment of AD. Additional 
treatments generally reserved for severe AD include phototherap y(eg, ultraviolet A light 
with or without psoralen, ultraviolet B light narrowband or broadband) andsystemic agents 
(eg, corticosteroids, cy closporine, recombinant IFN-, mycophenolate mofetil, methotrexate, 
azathioprine, IVimmunoglobulin).8Of the current ly available therapi[INVESTIGATOR_014], none offers a cure; 
therefore, the main aims of existing treatments are to reduce the occurrence of acute flares, 
to increase the time between relapses, and to reduce pruritus and the resulting sleep 
disturbance .9,[ADDRESS_1205120] been approved.
Dupi[INVESTIGATOR_12458], an injectable human monoclonal antibody  targeting IL -4 and -13,was approved 
by [CONTACT_69391] 2017 and received marketing authorization in Europe in September 
2017, and offers a novel mechanism of action for the treatment of moderate to severe AD. 
However, the approved dosing for dupi[INVESTIGATOR_74020] 2 × 300 mgsubcutaneous 
injections followed by  300 mg every  other week injections may  limit the desirability  of this 
route of treatment.
2.2.3. Rationale for 
Development of Abrocitinib
Abroc itinib is being developed as an oral treatment for participants with moderate to severe 
AD based on its mechanism of action, and the clinical results obtained in Phase 1 and 
Phase 2 studies. The clinical development program for abrocitinib includes healthy
participants, participants with psoriasis and participants with AD. 
Abrocitinib pediatric program will be initiated to fulfill the regulatory  requirements. Critical 
to the regulatory  requirements is the development and filing of a pediatric age -appropria te 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 22formulation for AD participants aged 6 months to <12 years, with rBA similar to currently  
developed abrocitinib commercial tablet and with acceptable palatability .Thus, this study  
will be conducted to estimate the rBA of an oral suspension formulation of abrocitinib 
compared to abrocitinib commercial tablet. The potential effects of alterations in 
gastrointestinal pH induced by  [CONTACT_864306] . A taste evaluation will also be conducted to 
assess the taste and palatability  of 6different oral suspension formulations for abrocitinib . 
The results of this taste assessment will help in guiding the selection and development of 
abrocitinib pediatrics formulation and info rm whether taste masking is required for the 
commercial pediatric formulation.
2.2.4. Nonclinical Pharmacology
Abrocitinib inhibits cy tokines implicated in AD pathogenesis. For example, in vitro,
abrocitinib inhibits IL -4 and IL -13 signaling in B cells, monocy tesand keratinocy tes, IL -4
signaling in T cells and IL-31 signaling in THP -1 cells. Abrocitinib also inhibits IL -22 in
keratinocy tes and IFN -, IFN-,IL-6 and other JAK1 dependent cy tokines in PBMCs and
human whole blood. The primary  human metabolites of abrocitinib (M1 and M2) showed a
profile of cy tokine inhibition, via JAK1- dependent pathway s, similar to the parent compound
abrocitinib, while M4 was pharmacologically  inactive. I n AIA rats, abrocitinib exhibited a
significant and maximal inhibition of disease for this model as well as significant inhibition
of cy tokine dependent STAT phosphory lation in ex vivo stimulated whole blood. Significant 
abrocitinib inhibition (>50%) of binding or enz yme activity  of MAO -A and KDR kinase 
(VEGFR2) was observed, with IC50values that were respectivel y 4.8x and 1.0x the unbound 
human C maxat a clinical dose of 200 mg QD. 
In vitro safet y pharmacology studies were conducted to assess potential hERG (GL P) and
Nav1.5 (non- GLP) inhibition and the I C50was 76x and 240x, respectivel y, at the unbound
human C max. These ion channel in vitro assessments satisfy  ICH S7A/B guidelines. I n the
broad ligand profile screen, less than 50% inhibition of calcium channel binding was
observed. Overall, the nonclinical in vitro data for abro citinib (and M1, M2, and M4) 
contribute to the weight of evidence for no significant effects at clinically  relevant 
concentrations on the primary cardiac ion channels (eg, hERG, Nav1.5, or Cav1.2) generally  
considered to be most important for risk assessme nt of QT prolongation.
In vivo safet y pharmacology studies were conducted to assess potential effects on the
nervous, cardiovascular, and pulmonary  systems. Abrocitinib produced lower locomotor
activity  (horizontal and vertical movements) and body  temperat ure in rats and increases in
heart rate and diastolic blood pressure in cy nomolgus monkey s. No other effects on
parameters in the FOB were observed or on the telemetry -based activit y measure in the rat or
cynomolgus monkey  cardiovascular safet y pharmacolog y studies were observed. No primary
QT signals, including no QTc prolongation, were observed in the cardiovascular safet y
pharmacology  study  in cy nomolgus monkey s.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 232.2.5. Nonclinical Pharmacokinetics and Metabolism
Plasma profiling from the [14C]abrocitinib human mass balance stud y indicated unchanged
abrocitinib as the most prevalent circulating species (26%), with [ADDRESS_1205121] sufficient exposures at NOAEL doses in rats (rat/human AUC 24ratios ≥
1) relative to the projected highest therapeutic human dose of 200 mg daily .
In vitro and in vivo metabolite profiling suggested that the primary  clearance mechanism for
abrocitinib was CYP -mediated oxidation , with CYP2C19 the primary contributor at 
approximately  50%. CYP metabolism play ed a minor role (<25%) in the clearance of 
metabolites M1, M2 and M4. Renal excretion of parent drug was limited in the mouse, rat 
and humans, while urinary excretion was the major route of elimination for M1, M2, and M4. 
Abrocitinib, M1, M2, and M4 were not significant competitive inhibitors of CYP enzy mes,
but showed vary ing weak TDI activities versus CYP3A, CYP2C19 and CYP2D6.
Abrocitinib exhibited a weak potential to induce CYP3A4 and CYP2B6, while the M1, M2,
and M4 did not show a greater risk of induction compared to abrocitinib. Clinical results with
midazolam as a victim indicated no significant risk of interaction through inhibition or
induction of CYP3A after abrocitin ib administration.
Abrocitinib, M1, M2, and M4 were not significant inhibitors of the major UGT enzymes. 
Abrocitinib did not significantly inhibit SUL T enzy mes. Clinical results with ethiny l 
estradiol as a victim indicated no significant risk of UGT or SUL T inhibition by  [CONTACT_864307].
Abrocitinib was not a substrate for OATP1B1 or OATP1B3, nor inhibited these transporters. 
Abrocitinib did not inhibit OAT1, OCT2, or bile salt export pump, but inhibited OAT3, P -gp, 
BCRP, OCT1, MATE1, and MATE2K. Clinical results showed abrocitinib co -administration 
increased dabigatran exposure <[ADDRESS_1205122] on the exposure of rosuvastatin (BCRP, 
OAT3 probe substrate) or metformin ( OCT2, MATE1/2K, OCT1 probe substrate).
Overall risk of a transporter interaction from M1, M2, and M4 is considered low and not
greater than from abrocitinib. M1, M2 and M4 were substrates of OAT3, but not MATE1,
MATE2K, OAT1 or OCT2. Clinical results with probenecid (an OAT3 inhibitor) 
coadministration significantly  increased exposure of M1, M2, and M4, but had no effect on
abrocitinib exposure.
2.2.6. Nonclinical Safety
Abrocitinib was assessed in a series of nonclinical toxicity  studies. In repeat -dose toxicity  
studies, abrocitinib was administered chronicall y to rats and cy nomolgus monkey s in studies 
up to [ADDRESS_1205123] abrocitinib- related effects had reversed b y the end of a 12 -week 
recovery  phase. 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205124] the male reproductive s ystem, including fertility  or
spermatogenesis, but did result in reversible decreased female fertility . Effects on female
fertility  (decreased fertility  index, corpora lutea, implantation sites) and increased post-
implantation loss were observed in rats at 70 mg/kg/day  and 30 mg/kg/day with exposures 
29x and ≥11, re spectively, the unbound human AUC at the clinical dose of [ADDRESS_1205125] on male fertility , and no histopathological changes were noted in the 
testes and epi[INVESTIGATOR_864291] 6 and 9 months at doses up 
to 70 and 75 mg/kg/day  in rats and cynomolgus 
monkey s, respectively , and corresponding 
exposures were 26x and 10x the unbound AUC at the human clinical dose of [ADDRESS_1205126] phototoxicity  potential.
2.2.7. Clinical Overview
[IP_ADDRESS]. Summary of Safety Data from C ompleted Studies
Based on the clinical experience with abrocitinib and its mechanism of action, the potential 
risks of treatment with JAK inhibitors include: (1) viral reactivation; (2) serious infection and 
opportunistic infections; (3) malignancy  and ly mphoproliferative disorders; (4) decreased 
lymphocy te counts; (5) decreased neutrophil counts; (6) decreased platelets; (7) alterations in 
the lipid profile ; and (8) venous thromboembolism (deep venous thrombosis/pulmonary  
embolism) .
In the completed Phase [ADDRESS_1205127] reported TEAEs were mild or moderate in 
severit y. In stud yB7451001, during the single -ascending dose phase, 1 participant in the 
placebo group had maximum QTcF interval of 450 -<480 msec, and 1 participant in the 
abrocitinib 800mg treatment group had maximum QTcF interval increase from baseline of 
30 to <60 msec. In the multiple -ascending dose phase, 3 participants (1 each in the placebo, 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 25abrocitinib 30mg QD, and 100 mg QD treatment groups) had maximum QTcF interval of 
450 - <480 msec, and 2 participants in the abrocitinib 200mg BID treatment group had 
maximu m QTcF interval increase from baseline of 30 to <60 msec. 
In the completed Phase 2 study  in participants with moderate to severe psoriasis (B7451005), 
the most frequentl y reported AEs across the abrocitinib treatment groups (200 mgBID, 
200mgQD, and 400 mg QD) were nausea, followed by  [CONTACT_12704]. Other commonly  reported 
AEs include neutropenia and neutrophil counts decreased, thrombocy topenia and platelet 
count decreased. One of the participants in the 200 mg QD group with an AE categorized as 
infections a nd infestations was reported as having VIIth nerve paral ysis (Bell’s palsy ) and 
later developed herpes zoster (shingles). The incidence of normal and abnormal ECG 
recordings was similar across all treatment groups at each time point. None of the abnormal 
ECG recordings were determined to be clinicall y significant b y the investigator.
In the completed 12-week Phase 2b study  (B7451006) in participants with AD, AEs and 
SAEs were numericall y higher in participants receiving abrocitinib (10, 30, 100, and 200 mg 
QD) compared to placebo, but did not appear to increase with dose. The most common AEs 
were in the infec tions and infestations, skin and subcutaneous tissue disorders and 
gastrointestinal disorders SOC, and the majority  of the AEs were mild. The most commonly  
reported TEAEs across all the treatment groups were dermatitis atopic (38 events), and viral 
upper r espi[INVESTIGATOR_2826] (33 events). The most frequently  reported treatment related
TEAE was nausea. There were 2 cases of nonserious herpes zoster, one in the 10 mg group 
(not treatment -
related), and one in the 30 mg group (treatment- related). There we re 
2participants (doses of ≥100 mg QD) with treatment related SAEs reported, the SAEs were 
eczema herpeticum and pneumonia. One participant randomized to the abrocitinib 10 mg 
group reported an SAE of malignant melanoma. Dose dependent mean platelet count
decreases from baseline were observed with a nadir at Week 4. At Week 4 the mean platelet 
count and the 90% CI were within the normal reference range for both the [ADDRESS_1205128] of the ECG results were normal. The incidence of normal and abnormal 
ECG recordings was similar between abrocitinib and placebo groups at each time point.
In the completed 12-week Phase 3 study  (B7451012) in adult and adolescent participants 
aged [ADDRESS_1205129] frequent all -causalit y TEAEs 
that occurred in ≥5% of participants of an y treatment group (100 mg QD and 200 mg QD) 
were nausea, nasophary ngitis, upper respi[INVESTIGATOR_2826], headache, and dermatitis 
atopic. Nausea was the most frequentl y reported treatment- related TEAE with ≥5% higher 
incidence in the abrocitinib treatment groups compar ed with the placebo group. Majority  of 
TEAEs reported were mild to moderate in severit y.
Similarly , safet y data from the completed 12 -week Phase 3 study  (B745101 3) in adult and 
adolescent 
participants aged [ADDRESS_1205130] frequent all -causalit y TEAEs that occurred in ≥5% of participants 
of an y treatment group (100 mg QD and 200 mg QD) were nausea, nasophary ngitis, upper 

Abrocitinib (PF-04965842)
B7451061Final Protocol, [ADDRESS_1205131] frequently
reported treatment-related TEAE with ≥5% higher incidence in the abrocitinib 200 mg 
treatment group compared with the placebo group. Majority of TEAEs reported were mild to moderate in severity.
[IP_ADDRESS]. Summary of Abrocitinib Pharmacokinetics, Metabolism and In Vitro 
Enzymology
[IP_ADDRESS].1. Single and Multiple Dose PharmacokineticsAbrocitinib was absorbed rapi[INVESTIGATOR_773976]/suspension doses of 3 mg to 
200 mg with median time to T
maxobserved less than 1 hour (ranging from 0.55 to 
0.77 hours), and more slowly at the higher doses with median T maxof 1.5 and 4.0 hours for 
the 400 mg and 800 mg doses, respectively  Following attainment of C max, 
the disposition of abrocitinib generally showed a monophasic decline at the lower doses of 3 to 30 mg (mean apparent t
½of 1.9 to 2.5 hours) while a biphasic decline was observed at 
doses of 100 to 800 mg with a mean t ½of 3.6 to 4.9 hours. Plasma abrocitinib C maxappeared 
to increase proportionally across the entire dose range from 3 mg to 800 mg, while increases in AUC
infwere greater than proportional at doses of 400 and 800 mg. For the 2-fold doses 
increase between 200 to 400 mg and between 400 to 800 mg, the mean AUC infvalues in 
Western participants in this study appeared to increase approximately 3.5- and 2.7-fold, respectively.
On Day 10 of multiple-dose administration, abrocitinib was absorbed rapi[INVESTIGATOR_377459] 
T
maxof about 1 hour or less (ranging from 0.50-1.05 hours) across the entire range of doses, 
from a total daily dose of 30 mg (30 mg QD) up to 400 mg (200 mg BID or 400 mg QD). Following attainment of C
max, the disposition of abrocitinib was consistent with that observed 
following single-dose administration, showing a biphasic decline following all but the lowest dose and a mean t
½of about 2.8 to 5.0 hours. Plasma C maxand AUC tauboth appeared to show 
a trend towards greater than proportional increases at doses higher than 200 mg given once-daily. Geometric mean values for the observed R
ac, that compares AUC taufor 
multiple-dose administration to AUC taufor single-dose administration, ranged from 
1.3 to 1.5 for QD dosing and 1.3 to 2.3 for BID dosing. Similar ratios for C maxcomparison 
(Rac,Cmax) ranged from 1.1 to 1.3 for QD dosing and from 1.3 to 2.8 for BID dosing. These 
results showed that drug concentration accumulation after repeated oral QD or BID 
administration is less than about 1.5- and 2.3-fold, respectively; at doses up to 200 mg QD, the accumulation was minimal and generally consistent with the prediction from t
½. 
At a single 800-mg dose, the geometric mean C maxwas similar in Western and Japanese 
participants. However, geometric mean AUC infwas 26% higher in Western participants than 
that observed in Japanese participants. Geometric mean C maxand AUC taufollowing 
multiple-dose administration of 200 mg BID was 17% and 56% higher, respectively, in the Western participants than in Japanese participants. 
The urinary recovery of abrocitinib was low, with <4% of the dose recovered unchanged in 
urine across all doses and regimens in all cohorts in  
CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, [ADDRESS_1205132] crossover study in 12 healthy participants under fasting and fed conditions  Following single oral 400 mg doses under fasted conditions, C
maxwas reached rapi[INVESTIGATOR_864292] (median T max
0.52 hours) and more slowly for the tablet formulation (4 × 100 mg, median T max2.0 hours). 
When the tablet was administered under fed conditions, T maxwas further delayed with a 
median value of 4.0 hours. Mean t ½was 4.9 hours for the oral suspension fasted, 5.3 hours 
for the tablet fasted, and 3.2 hours for the tablet under fed conditions. Relative BA of 4 × 100 mg abrocitinib tablets compared to 400 mg oral suspension under fasted condition was 96.54% and the 90% CI for the ratio (tablet/suspension) of adjusted geometric mean AUC
infvalues was (90.31%, 103.21%), within the 80% to 125% interval demonstrating 
equivalence of total exposure. The ratio (90% CI) for C maxwas 79.48% (62.88%, 100.46%). 
Administration of 4 × 100 mg abrocitinib tablets with food did not change AUC infand 
appeared to result in slightly lower C maxwith reduced variability compared to fasted 
conditions. The ratio (90% CI) of adjusted geometric means for fed/fasted administration was 100.70% (94.42%, 107.40%) for AUC
infand 95.56% (76.22%, 119.82%) for C max. The 
magnitude of decrease in C max(<5%) was not considered to be clinically important. 
Therefore, abrocitinib can be administered with or without food. There were no clinically significant changes in ECG findings during the study.
[IP_ADDRESS].2. Metabolism and In Vitro Enzymology
In vitro and in vivo metabolite profiling in rat, monkey, and human indicated that the primary 
clearance mechanism for abrocitinib was CYP-mediated oxidative metabolism. No unique human metabolites were observed clinically compared to metabolite profiling in rat and monkey. There was no evidence of chiral inversion in human plasma samples. Plasma profiling from the [
14C]abrocitinib human mass balance study indicated parent as the most 
prevalent circulating species (26%), with 3 major and more polar mono-hydroxylated metabolites identified: 340-1 (3-hydroxyp ropyl, 11%), 340-2a (2-hy droxypropyl, 12%), and 
340-4 (pyrrolidinone pyrimidine, 14%).
In vitro human CYP450 phenotypi[INVESTIGATOR_773978]2C19 (fraction metabolized 
[fm] ~0.5), CYP2C9 (fm ~0.3), CYP3A4 (fm ~0.1), and CYP2B6 (~0.1) were involved in 
the metabolism of abrocitinib. Early assessment of clinical genotypes from FIH participants
indicated PK variability of all available non-wild-type genotypes (CYP2C19*1/*2, *2/*3, *2/*2, *1/*17, and *17/*17; CYP2C9*1/*2, *1/*3) were within the variability seen in wild-type CYP2C9*1/*1 and CYP2C19*1/*1 participants. 
Abrocitinib did not inhibit the major CYP enzymes (IC
50values >100 μM) by [CONTACT_864308]-dependent inhibition without the reduced form of NADPH. In the presence of NADPH, abrocitinib caused relatively weak time-dependent inhibition of CYP2C19 (IC
50,4 2μM), CYP2D6 (IC 50, 92μM), and CYP3A4/5 (IC 50, 40 to 81 μM).
Abrocitinib concentration dependently induced CYP3A4 mRNA in 2/3 hepatocyte lots at 
≥10μM and CYP2B6 mRNA in 3/3 hepatocyte lots at ≥10μM. Enzyme activity of CYP2B6 
increased >2-fold at ≥30μM in 1 of 3 lots of hepatocytes. Conversely, abrocitinib caused a 
concentration-dependent decrease in CYP3A4 and CYP1A2 enzyme activities in CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 283/3 hepatocyte lots. Clinically, abrocitinib PK showed apparent dose proportionality of single 
and multiple daily doses up to 200 mg, with no significant changes (~ <20%) in the CYP3A 
plasma biomarker 4 β-hydroxycholesterol/cholesterol ratio following 10 days of dosing 
Preliminary SimCYP®modelling of abrocitinib dosed 200 mg QD for 
10 days indicated a low risk of precipi[INVESTIGATOR_2505] a significant drug interaction with midazolam (CYP3A), buproprion (CYP2B6), or mephenytoin (CYP2C19). 
Abrocitinib did not inhibit the major UGT enzymes; all IC
50values >100 μM. Abrocitinib
was not a substrate for OATP 1B1 or OATP1B3, nor inhibited these transporters (IC 50values 
>300μM). Abrocitinib did not inhibit OAT 1 (IC 50>300μM) or OCT 2 (IC 50>300μM), but 
weekly inhibited OAT3 (IC 50= 26μM), MDR1 (IC 50= 100μM), OCT1 (IC 50=4 4μM), and 
showed some inhibitory activity of BCRP (IC 50= 9.8μM), MATE1 (IC 50= 5.5μM), and 
MATE2K (IC 50= 10.7μM). Clinically, abrocitinib did not significantly affect 24 hour
urinary creatinine (OCT2 and MATE1/2K substrate) up to doses of 800 mg (Study B7451001). Preliminary SimCYP
®modelling of abrocitinib dosed at 200 mg QD 
indicated a low risk of precipi[INVESTIGATOR_2505] a significant drug interaction with metformin (OCT2/MATE substrate) or digoxin (MDR1 substrate).
 
 
 
2.3. Benefit/Risk Assessment
Abrocitinib is not expected to provide any clinical benefit to healthy participants. This study 
is designed primarily to generate safety, tolerability, and PK data for further clinical development.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of abrocitinib may be found in the IB, which is the SRSD for this study. The SRSD for the ARA, famotidine, is the US package insert.CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 293. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary: 
Part A:
•Estimate the rBA of abrocitinib 200 mg oral 
suspension formulation 1 compared to the 
1×200 mg of abrocitinib commercial tablet under fasting condition.
•Evaluate the effect of a single dose of an ARA
(famotidine 40 mg) on the BA of abrocitinib 1×200 mg commercial tablet under fasting conditions.•Plasma abrocitinib PK parameters: AUC
inf(if 
data permit), AUC lastand C max after 
administration of abrocitinib oral suspension formulation and commercial tablet.
•Plasma abrocitinib PK parameters: AUC
inf (if
data permit), AUC lastand C maxafter 
administration of ARA plus abrocitinib commercial tablet.
Part B:
•Evaluate the taste and palatability of 
6 abrocitinib suspension formulations using a 200 mg dose.•Taste Assessment Survey Scoring Metrics after 
suspension formulation: mouthfeel, bitterness, tongue/mouth burn, saltiness, sourness, and overall liking.
Secondary: Secondary: 
 
 
•Determine the PK of metabolites (M1, M2 and 
M4) following the administration of 1×200 mg of abrocitinib commercial tablet with or without an ARA (famotidine 40 mg) in Part A.
•Evaluate the safety and tolerability following 
oral administration of each of the abrocitinib formulations in Parts A and B.•PK parameters: AUC
inf(if data permit), AUC last
and C maxafter administration of 1×200 mg of 
abrocitinib commercial tablet with or without an ARA.
•Assessment of TEAEs, clinical laboratory tests, 
vital signs, and 12-lead ECGs.
 
 
 
 
4. STUDY DESIGN
4.1. Overall DesignThis is a Phase 1 randomized, crossover study in healthy participants to estimate the rBA of 
abrocitinib oral suspension (Test formulation) compared to commercial abrocitinib tabletCCIC
CIC
C
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 30(Reference formulation) under fasted condition. The effect of ARA on the BA of abocitinib 
and its metabolites will be evaluated by [CONTACT_864303] 200 mg commercial tablet with or without famotidine 40 mg as an ARA. Part B is to assess the taste and palatability of 6 different abrocitinib oral suspension formulations, to guide the selection and development of abrocitinib pediatrics oral suspension formulation. 
This study consists of 2 parts, as listed below.
Part A: This part of the study will be an open label, randomized, single dose, crossover, 
3-treatment, 6-sequence, 3-periods design. Approximately 18 healthy male and/or female participants (18-55 years) will be enrolled and randomized to 1 of 6 possible treatment sequences. Participants who discontinue from the study may be replaced at the sponsor’s discretion. The replacement participant will receive the same treatment sequences as the participant who discontinued. Each randomized treatment sequence will consist of 3 treatment periods as shown in Table 4.
Table 4. Randomized Treatment Sequences of Part A
Sequence Period 1 Period 2 Period 3
1 (n=3) A B C
2 (n=3) B C A
3 (n=3) C A B
4 (n=3) A C B
5 (n=3) B A C
6 (n=3) C B A
Treatment A = Abrocitinib 200 mg commercial tablet only, under fasted conditions.
Treatment B = Abrocitinib 200 mg oral suspension formulation 1, under fasted conditions.Treatment C = Famotidine [ADDRESS_1205133] administration of the 
study intervention to confirm that they meet the participant selection criteria for the study. Eligible participants will be admitted to the CRU on Day -1 and will be confined in the CRU until Discharge, which is Day 2 of Period 9, in Part B of the study ( SoA), after completing 
both Parts A and B of the study. Day -[ADDRESS_1205134] day of dosing (Day 1). 
In Period 1 through Period 3 of Part A, participants will receive a single 200 mg dose of 
abrocitinib commercial tablet (Treatment A), a single 200 mg dose of abrocitinib oral suspension (Treatment B), or 40 mg famotidine tablet administered 120 minutes prior to a single dose of 200 mg dose of abrocitinib commercial tablet (Treatment C) after a fast of at least [ADDRESS_1205135] 10 hours before taking abrocitinib.  
CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 31 
Part B: 
Participants who complete Part A of the study are expected to proceed to Part B. Part B will 
be a single-blind, randomized, 6-period, cross-over study in healthy male and/or female adult participants (18-55 years). A total of 18 healthy participants will be enrolled and randomized to 1 of 6 possible treatment sequences. Participants who discontinue from the study may be replaced at the sponsor’s discretion. The replacement participant will receive the same treatment sequences as the participant who discontinued. Each randomized treatment sequence will consist of 6 treatment periods (Table 5).
Table 5. Randomized Treatment Sequences of Part B
Sequence Period 4 Period 5 Period 6 Period 7 Period 8 Period 9
1 (n=3) F1+ARA F2+ARA F3+ARA F4+ARA F5+ARA F6+ARA
2 (n=3) F6+ARA F1+ARA F2+ARA F3+ARA F4+ARA F5+ARA
3 (n=3) F5+ARA F6+ARA F1+ARA F2+ARA F3+ARA F4+ARA
4 (n=3) F4 F5 F6 F1 F2 F3
5 (n=3) F3 F4 F5 F6 F1 F2
6 (n=3) F2 F3 F4 F5 F6 F1
F1 = Abrocitinib oral suspension formulation 1 under fasted conditions.
F2 = Abrocitinib oral suspension formulation 2 under fasted conditions.
F3 = Abrocitinib oral suspension formulation 3 under fasted conditions.F4 = Abrocitinib oral suspension formulation 4 under fasted conditions.F5 = Abrocitinib oral suspension formulation 5 under fasted conditions.F6 = Abrocitinib oral suspension formulation 6 under fasted conditions.ARA = Famotidine [ADDRESS_1205136] administration of the study intervention to confirm that they meet the participant selection criteria for the study. 
Abrocitinib oral suspension formulations 1 to 6 for tasting will be offered to all participants 
in a blinded fashion. Participants randomized to Sequence 1-3 will receive famotidine (40 mg with 240 mL of room temperature water) [ADDRESS_1205137] 10 hours before taking abrocitinib. CCI
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205138] 10 hours before taking abrocitinib.
New participants enrolled in Part B only  will be admitted to the CRU on Day  -1 and will be 
confined in the CRU until Discharge, which is Day 2 of Period 9. On Day 1 of each treatment 
period under fasted conditions, participants will receive famotidine tablet (40 mg with 
240mL of room temperature water) administered 120 minutes befor e  a single 200 mg dose 
of abrocitinib oral suspensions (Formulations 1 to 6) or administered a single 200 mg dose of 
abrocitinib oral suspension alone (Formulations 1 to 6), after a fast of at least [ADDRESS_1205139] is approximately  10weeks. Participants who discontinue from the study  
may be replaced at the sponsor’s discretion. The replacement participan t will receive the 
same treatment sequences as the participant who discontinued.
4.2.Scientific Rationale for Study Design
Part A: A crossover design was used in the rBA part of the study  following the FDA 
guidance which states that a crossover stud y design is recommended for BA of IR dosage 
forms. This crossover design reduces variability  caused by  [CONTACT_4676] -specific factors, thereby  
[CONTACT_864309] .11
Washout period: The mean elimination half -life of abrocitinib is approximately  3-5 hours; 
thus, a [ADDRESS_1205140] of an ARA on abrocitinib BA. This as sessment 
has been conducted following the FDA guidance recommending that sponsors need to assess 
the susceptibility  of a weak base drug, like abrocitinib, to DDI  mediated by [CONTACT_6026] -pH 
changes (referred to as pH
-dependent DDIs). FDA guidance states that co ncomitant 
administration of an ARA with a weak base drug could alter the BA of the drug. According 
to the FDA guidance, when evaluating the effect of DDI mediated b y gastricpH, it is 
preferable to select an ARA that does not exhibit other interacting mech anisms. The effect of 
PPI [INVESTIGATOR_864293]2C19 makes it a nonpreferable ARA selection to use in this study  as it may  
interfere with abrocitinib metabolism via CYP2C19. Administration of H2 blockers (eg, 
famotidine) ahead (eg, 2 hours) of the investigational drug can maximize the pH -elevating 
effect with a duration of action lasting ~10 -12 hours.12,13Famotidine is a competitive 

Abrocitinib (PF-04965842)
B7451061Final Protocol, [ADDRESS_1205141] occurred within 1 hour; the maximum effect was dose-dependent, occurring within 1 to 3 hours.
14Intragastric pH after a 
single dose of famotidine 40 mg was shown to rapi[INVESTIGATOR_864294] >4.[ADDRESS_1205142]-case scenario possible.
16
Part B: In Part B, treatments will be presented to the participants in a blinded fashion to 
minimize the potential bias for taste evaluation.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 34Figure 1. Abrocitinib pH Solubility Curve
 
 
 
 
 
 
4.2.1. Choice of Contraception/Barrier Requirements 
Human reproductive safety data are not available for abrocitinib, but there is no suspi[INVESTIGATOR_22742]. Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).
 
4.3. Justification for Dose
Single oral doses of [ADDRESS_1205143] 200-mg tablet strength intended for commercialization in both adults and adolescents. Similarly, Part B of the study will include suspension formulations of 200-mg strength, similar to the strength used for abrocitinib commercial tablet.
Following administration of a single oral dose of abrocitinib to healthy participants 
 systemic exposure to abrocitinib increased with dose in an approximately 
dose proportional manner up to 200 mg, suggesting linear PK over this dose range. Oral 012345678910111213
[ZIP_CODE] 1 0 1 2 1 4Solubility (mg/mL)
pH
CCICCICCI
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 35doses of abrocitinib as high as 800 mg (single dose), 400 mg QD and 200 mg BID (up to 
10days) have been found to be safe and well -tolerated. Administration of 400 mg abrocitinib
with food did not increase the exposure. Based on the safet y data of abrocitinib and prior 
clinical experience described above, the 200 mg single dose is expected to pose little risk to 
healthy  adult participants.
In the present stud y, the maximum allowed dose of famotidine, famotidine 40 mg, will be 
administered 2 hours before abrocitinib to achieve its maximal acid -reducing and pH -
increa sing effects. Intragastric pH after a single dose of famotidine 40 mg was shown to 
rapi[INVESTIGATOR_864295] >4.[ADDRESS_1205144] completed the study  if he/she has completed all periods of 
the study ,including the last Follow -up phone call.
5.STUDY POPULATION
This study  can fulfill its objec tives only  if appropriate participants are enrolled. The 
following eligibility  criteria are designed to select participants for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into c onsideration when deciding whether a particular participant is suitable for this 
protocol. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1.Inclusion Criter ia
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Male and/or female participants must be 18 to 55 years of age, inclusive, at the time 
of signing the ICD.
Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1) and female 
(
Section 10.4.2 ) participants.
a.Male participants:
No contraceptive measures are required.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
)
Page 36b.Female participants :
A female participant is eligible to participate if she is not pregnant or 
breastfeeding, and at least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3);
OR
Is a WOCBP and using a contraceptive method that is highly  effective 
(with a failure rate of <1% per year), as described in the Contraceptive and 
Barrier guidance (Appendix 4 ), during the intervention period and for at 
least 
[ADDRESS_1205145] dose of study  intervention, which corresponds 
to the time needed to eliminate any  reproductive safet y risk of the stud y 
intervention(s). The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.
A WOCBP must have a negative highly  sensitive (sensitivity  of at least 
25mIU/mL) pregnancy  test result at screening. Following a ne gative 
pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy  test result will be required 
prior the participants receiving the first dose of study intervention and at 
every  subsequent study  timepoints as per the SoA tables, to confirm the 
participant has not become pregnant.
The investigator is responsible for review of medical history , menstrual 
history , and recent sexual activity  to decrease the risk for i nclusion of a 
woman with an early  undetected pregnancy .
Type of Participant and Disease Characteristics:
2.Male and/or female participants who are overtl y healthy as determined b y medical 
evaluation including a detailed medical history , complete phy sical exa mination, 
laboratory  tests, and cardiovascular tests.
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
Weight:
4.BMI of 17.5 to 30.5 kg/m2; and a total body  weight >50 kg (110 lb). 
Informed Consent:
5. Capable of giving signed informed consent as described in Section 10.1.2, which 
includes compliance wit
h the requirements and restrictions listed in the I CD and in 
this protocol.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 375.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, p sychiatric, neurological, or 
allergic disease (including drug allergies, but excluding untreated, a symptomatic, 
seasonal allergies at the time of dosing).
2.Any condition possibly  affecting drug absorption (eg, gastrectomy ).
3.Participants with moderate to severe GERD s ymptoms (ie, heartburn and/or 
regurgitation) during the last 6 months.
4.History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, 
HBcAb or HCVAb. Hepatitis B vaccination is allowed.
5.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
6.Evidence or history  of clinically  significant dermatological condition (eg, AD or 
psoriasis) or visible rash present during ph ysical examination.
7.History of TB (active or latent) or inadequat ely treated TB infection. Positive 
QuantiFERON®–TB Gold test. 
8.Any history  of chronic infections, any  history  of recurrent infections, an y history  of 
latent infections, or an y acute infection within 2 weeks of baseline (Day  -1). 
9.History  of disseminated herpes zoster, or disseminated herpes simplex, or recurrent 
localized dermatomal herpes zoster. 
10.Have an y malignancies or have a history
 of malignancies with the exception of 
adequatel y treated or excised nonmetastatic basal cell or squamous cell cancer of the 
skin, or cervical carcinoma in situ . 
11.History  of hypersensitivity , intolerance, or allergic reaction associated to prior 
exposure to famotidine or other H2 -receptor antagonists excipi[INVESTIGATOR_840].
Prior/Concomitant Therapy:
12.Use of prescription or nonprescript ion drugs and dietary  and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . (Refer to Section 6.8 for additional details).

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205146] live components (or live 
attenuated vaccines) within the [ADDRESS_1205147] dose of abrocitinib or who 
are expected to be vaccinated during treatment or during the 6 weeks following 
discontinuation of abrocitinib.
NOTE regarding COVID vaccines with authorization or approval for 
emergency use:
There is no requirement for washout of COVID vaccines prior to t he first dose of 
abrocitinib if the vaccine is not live attenuated (eg, mRNA, utilizing a viral vector, 
inactivated virus). 
There is no protocol -specified requirement for the interruption of abrocitinib dosing 
prior to or after vaccination if the COVID vaccine is not live attenuated.
Prior/Concurrent Clinical Study Experience:
14.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_1205148] dose of study  intervention
used in this study  (whichever is longer). 
Diagnostic Assessments:
15.A positive urine drug test.
16.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_1205149]. If BP is ≥140 mmHg (s ystolic) or ≥90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility .
17.Baseline standard 12-lead ECG thatdemonstrates clinically relevant abnormalities that 
may affect participant safety or interpretation of study results (eg, baseline QTc F
interval >[ADDRESS_1205150] degree AV block, or serious bradyarrhy thmias 
or tachy arrhy thmias). If the baseline uncorrected QT interval is >450 msec, this 
interval should be rate -corrected using the Fridericia method and the resulting 
QTcF -should be used for decision making and reporti ng.If QTcFexceeds 450 msec, 
or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average 
of the 3 QTcFor QRS values should be used to determine the participant’s eligibility . 
Computer -interpreted - ECGs should be interpreted by a ph ysician experienced in 
reading ECGs before excluding a participant.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
)
Page 3918. Participants with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary : 
AST/ SGOT orALT/ SGPT level1.5 × ULN.
TBili level >1.0 ×ULN; participants with a history  of Gilbert ’s syndrome may 
have direct bilirubin measured and would be eligible for t his study  provided the 
direct bilirubin level is 1.0 × ULN.
eGFR 80 mL /min/1.73 m2(seeAppendix 2 for CKD -EPI [INVESTIGATOR_14420]).
19. Participants with abnormal complete blood count test results (eg, hemoglobin, 
platelets, WBCs- including l ymphocy tes, neutrophils) asassessed b y the 
study -specific laboratory , and confirmed b y a single repeat test, if deemed necessary .
Other Exclusions:
20.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of S creening. Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit = 8 ounces [240 mL]beer, 
1ounce [30mL]of 40% spi[INVESTIGATOR_107060] 3 ounces [90mL]of wine).
21.Pregnant female participants; breastfeeding female participants; female participant s of 
childbearing potential who are unwilling or unable to use 1 highl y effective method 
of contraception as outlined in this protocol (seeAppendix 4 , Section 10.4.4 )for the 
duration of the study
 and for at least [ADDRESS_1205151] dose of study  intervention .
22.Use of tobacco- or nicotin e-containing products in excess of the equivalent of 
5cigarettes per da y.
23.Blood donation (excluding plasma donations) of approximately 1pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_1205152] of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family  
members. 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
)
Page 405.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participants must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PK sample.
Water is permitted until 1 hour prior to study  intervention administration. Water may  
be consumed without restriction beginning 1 hour after abrocitinib dosing on Day 1 
of each treatment period. Noncaffeinated drinks (e xcept grapefruit or 
grapefruit -related citrus fruit juices—see below) may  be consumed with meals and 
the evening snack.
Lunch will be provided approximately  4-5hours after abrocitinib dosing.
Dinner will be provided approximately  9to 10 hours after abroc itinib dosing.
An evening snack may  be permitted.
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_1205153] 
dose of abrocitinib and during confinement in the CRU.
While participants are confined, their total daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat ,and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2. Caffe ine, Alcohol, and Tobacco
Participants will abstain from caffeine -
containing products for 24 hours prior to the 
start of dosing and during confinement in the CRU.
Participants will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol throughout their 
stay at the CRU . Participants may  undergo an alcohol breath test or blood alcohol test 
at the discretion of the investigator.
Participants will abstain from the use of tobacco -or nicotine -
containing products for 
24 hours prior to dosing and during confinement in the CRU. 
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 41In order to standardize the conditions on PK sampling day s, participants will be 
required to refrain from ly ing down (except when required for BP, pulse rate, and 
ECG measurements), eating, and drinking beverages other than water during the first 
4hours after abrocitinib dosing .
5.3.4. Contraception 
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant from the permitted list of contraception methods (see Appendix 4 , Section 10.4.4)
and will confirm that the participant has been instructed in its consistent and correct use. At 
time points indicated in the SoA, the 
investigator or designee will inform the participant of 
the need to use highl y effective contraception consistently  and correctly  and document the 
conversation and the participant’s affirmation in the participant’s chart (participants need to 
affirm their consistent and correct use of at least 1 of the selected methods of contraception)
considering that their risk for pregnancy  may  have changed since the last visit . In addition, 
the investigator or designee will instruct the participant to call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the participant
or partner .
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention/enrolled in the study . Screen 
failure data are collected and remain as source and are not reported on the DCT .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescree nedif they fail the screening evaluation for reasons related to incidental transitory  
conditions
. If a participant cannot return for the Baseline visit (the day  of first dose 
administration) within the protocol specified screening period of 28 day s (ie, Screening visit 
to Day 1 of Period 1 in Part A; or Screening visit to Day  1 of Period 4 for any  new 
participants enrolled in Part B of the study  only), the participant will be considered a scr een 
failure. If a participant is rescreened, a second informed consent must be obtained and 
documented, and all screening tests and procedures must be repeated. All results must be 
obtained before the participant may  receive the first dose of study  interve ntion .
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to study  intervention .
6.1.Study Intervention(s) Administered
For this study , commercial tablet formulation of abrocitinib 200 mg tablet ,6 oral suspension 
formulations of abrocitinib and famotidine 40 mg tablets will be administered . Commercial 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
)
Page 42tablet of abrocitinib 200 mg for oral administration will be supplied to the CRU as packaged 
bulk bottles and labeled according to local regulatory  requirements. The packaged bulk 
bottles will be provided to the site for dispensing by  [CONTACT_1714] . 
Abrocitinib 25 mg/mL oral suspension will be supplied as a white to off-white read y to use 
suspension, packaged in a 75 mL  HDPE white, round bottle with a heat induction seal and 
white child resistant cap. Each bottle of abrocitinib will contain 60 mL  of oral suspension. As 
part of a rBA in Part A and taste assessment study in Part B, 25 mg/mL suspensions of 
abrocitinib will be dosed to participants. Six suspension formulations will be evaluated in the 
study , the first suspension formulation (Formulation 1) will be used for PK assessment, in 
Part A of the stud y, and taste evalu ation, in Part B of the study . While, the 5others 
(Formulation 2 -6) will be used only  in Part B of the study  for taste evaluation only  as 
outlined in Table 
6. 
Famotidi ne 40 mg tablets will be supplied by  [CONTACT_47365].

Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 43Table 6. Summary of Abrocitinib Oral Suspension Formulations to be administered for PK and Taste Assessment
Formulation Supply Use
1Provided by [CONTACT_864310] D1900119
Abrocitinib 25 mg/mL Oral Suspension in 75 mL HDPE bottle 
(60 mL)PK + Taste Evaluation
2Provided by [CONTACT_864311] D1900120
Abrocitinib 25 mg/mL Oral Suspension in 75 mL HDPE bottle 
(60 mL, without flavour)Taste Evaluation only
3 Prepared at CRU
4 Prepared at CRU
5 Prepared at CRU
6 Prepared at CRUCCI
CCI
CCI
CCI
CCI
CCICCI
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 446.1.1. Administration
Part A: Following an overnight fast of at least 10 hours, participants will receive the study  
intervention , abrocitinib ,at approximately  0800 hours (plus or minus 2 hours). Investigator 
site personnel will administer the study  intervention during each period with ambient 
temperature water to a total volume of approximately  [ADDRESS_1205154] 10 hours before taking abrocitinib .
Part B: Abrocitinib oral suspension formulations [ADDRESS_1205155] 10 hours, participants 
will receive 
the study intervention , abrocitinib, at approximately  0800 hours (plus or minus 
2hours). Participants will place samples into their mouths, swish the sample in the mouth for 
approximately  [ADDRESS_1205156] the sensory  
attributes at timed intervals of 0 (immediatel y after dosing), 5, [ADDRESS_1205157] 
10hours before receiving abrocitinib . Water will be withheld for 1-hour predose and 1 hour 
after stud y treatment admini
stration, and food will only  be allowed after 4 hours postdose.
In order to standardize the conditions throughout the study , all participants will be required to 
refrain from l ying down (except when required for BP, pulse rate, and ECG measurements), 
eating, and drinking beverages other than water during the first [ADDRESS_1205158] be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) ar ea in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205159] be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the PCRU local/site procedures .
4.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
5.Study  interventions should be stored in their original containers.
6.
See the DAI for storage conditions of the study  intervention once reconstituted.
7.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records ), such as the 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a study intervention accountabilit y form/record.
8.Further guidance and information for the final disposition of unused study  
interventions are provided i n the PCRU local/site procedures . All destruction must be 
adequatel y documented. If destruction is authorized to take place at the investigator 
site, the investigator must ensure that the materials are destro yed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007].
Upon identification of a product complaint, notify the sponsor within 1 business day  of 
discovery .
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to t he investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479]. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, or to a 
participant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may  use alternative terms for these activities.
Abrocitinib
tablets will be dispensed at the CRU in the individual dosing containers by  
2operators, one of whom is an appropriatel y qualified and experienced member of the stud y 
staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, pharmacy  

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 46assistant/technician, or pharmacist). The tablets will be provided in unit dose containers and 
labeled in accordance with [COMPANY_007] regulations and the clinical site’s labeling requirements.
For the oral suspension formulations of abrocitinib , see the DAI for instructions on how to 
prepare the study  intervention for administration. Study  intervention should be prepared and 
dispensed by  [CONTACT_864312] (eg, 
physician, nurse, phy sician’s assistant, nurse practitioner, pharmac y assistant/technician, or 
pharmacist) as allowed by  [CONTACT_5737], state, and institutional guidance. A second staff member will 
verify  the dispensing.
The handling of famotidine tablets should be according to the product package insert.
6.3.Measures to Minimize Bi as: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
The investigator, or delegated staff, will assign participant numbers to the participants as they  
are screened for the study. [COMPANY_007] will provide a randomization schedule to the investigator 
and, in accordance with the randomization numbers, the participant will receive the st udy 
treatment regimen assigned to the corresponding randomization number.
6.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the DCT . 
Study  site personnel will examine each participant’s mouth to ensure that the study  
intervention was ingested.
6.5. Dose Modification
Dose modification is not allowed in this study . 
6.6.Continued Access to Study Intervention A fter the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of abrocitinib greater than 800 mg within a 24- hour time period 
(±12 hours) will be considered an overdose.
The sponsor does not recommend specific treatment for an overdose for abrocitinib . 
Observation and if required, supportive care would be expected.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 47In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours.
2.Closely monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of abrocitinib (whichever is 
longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
theDCT .
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within [ADDRESS_1205160] dose of 
study  intervention if requested by  [CONTACT_7195] (determined on a case -by-case
basis).
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_78256].   
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . 
Vaccines with live components (or live attenuated vaccines) are prohibited within the 
6weeks prior to the first dose of abrocitinib, during the study  treatment and during the [ADDRESS_1205161]
udy may  be permitted on a case -by-case basis following 
approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of ≤1g/day .
Hormonal contraceptives that meet the requirements of this study  are allowed to be used in 
participants who are WOCB P (see Appendix 4 ).
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration. All participants will be questioned about 
concomit ant treatment at each clinic visit.
Treatments taken within [ADDRESS_1205162] dose of study  intervention
will be documented as concomitant treatment s.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 486.8.1. Rescue Medicine
There is no rescue therapy to reverse the AEs observed with abrocitinib ;standard medical 
supportive care must be provided to manage the AEs. 
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAW AL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following: 
AE requiring discontinuation in investigator’s vi ew;
Pregnancy ;
Positive COVI D-[ADDRESS_1205163].
If study  intervention is permanentl y discontinued, the participant will not remain in the study 
for further evaluation. See the SoA for data to be collected at the time of discontinuation of 
study  intervention.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further stud y procedures;
Lost to follow -
up;
Death;
Study  terminated by  [CONTACT_3211];
Behavioral, compliance or administrative reasons.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .If the participant wi thdraws from the 
study  and also withdraws consent (see Section 7.2.1 ) for disclosure of future information, no 
further evaluations should be performed and no additio nal data should be collected. The 
sponsor may retain and continue to use any  data collected before such withdrawal of consent.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205164] 
with him or her or persons previously  authorized by  [CONTACT_19983]. Participants should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate DCT page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol low-up 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining the 
assigned visit schedule , and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AN
D PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205165] reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll from an earlier group may  be 
used in a subsequent group without rescreening, provided laboratory results obtained prior to 
the first dose administration meet elig ibility  criteria for this study . In addition, other clinical 
assessments or specimen collections, eg, retained research samples , may  be used without 
repeat collection, as appropriate. 
Immediate safety
 concerns should be discussed with the sponsor immediat ely upon 
occurrence or awareness to determine if the participant should continue or discontinue study  
intervention.
Every  effort should be made to ensure that protocol required tests and procedures are 
completed as described. However, it is anticipated tha t from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
wellbeing of the participant. When a protocol required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The stud y team must be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_864313] n of the study .
The total blood sampling volume for individual participants in this study  is approximately  
230mL per participant. The actual collection times of blood sampling may  change. 
Additional blood samples may  be taken for safety assessments at times specified b y [COMPANY_007], 
provided the total volume taken during the stud y does not exceed 550 mL during an y period 
of 60 consecutive day s.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 51To prepare for stud y participation, participants will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy of the protocol.
8.1.Efficacy Assessments
Not Applicable .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the study  to assess any  
perceived safety  issues.
8.2.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, head, ears, ey es, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief ph ysical examination will include, at a min imum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and participant- reported s ymptoms. 
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulk y layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical ex amination findings collected during the study  will be considered source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE (Appendix 3 )must be reported according to the processes in 
Section 8.3.1 to Section 8.3.3.
8.2.2. Vital Signs
Supi[INVESTIGATOR_864296]. 
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
Supi[INVESTIGATOR_78235]’s arm supported at the level of the heart and 
recorded to the nearest mm Hg after approximately [ADDRESS_1205166]. The same arm 
(preferabl y the dominant arm) will be used throughout the study . Participants should be 
instructed not to speak during measurements. 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 52The same properl y sized a nd calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
[IP_ADDRESS]. Temperature
Temperature will be measured orall y. No eating, drinking, or smoking is allowed for 
[ADDRESS_1205167] 12
-lead E CGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex . Alternative lead placement methodology using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safet y of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥60 msec from the baseline andis >450 msec ; or b) 
an absolute QT value is ≥
500msec for an y scheduled ECG. If either of these conditions 
occurs, then [ADDRESS_1205168] hourl y until QTc values from 
2successive ECGs fall below the threshold value t hat triggered the repeat measurement.
If a) a postdose QTcF interval remains ≥60 msec from the baseline andis >450 msec; or b) 
an absolute QT value is ≥500 msec for an y scheduled ECG for greater than 4 hours (or 
sooner , at the discretion of the investigat or);or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring. A cardiologist should be 
consulted if QTc F intervals do not return to less than the criteria listed above after 8 hours of 
monitoring (or sooner ,at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine- read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 7 .

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205169] . 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_1205170] dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the inves tigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix [ADDRESS_1205171] will be performed after 4 day s 
(ie,upon completion of 4 × 24 hours in- house), or if they  develop COVID- [ADDRESS_1205172] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA. 
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced, and a second negative pregnancy  test result will be required at the baseline visit 
(admission during Period 1), prior to the participant’s receiving the study  intervention . 
Pregnancy  tests will also be done whenever 1 menstrual cy cle is missed during the active 
treatment period (or when potential pregnancy  is otherwise suspected) and at 
the end of the 
study . Pregnancy  tests may  also be repeated if requested by  [CONTACT_1202]/ECs or if required b y local 
regulations.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 548.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
study  intervention (see Section 7.1).
During the active collection period as described in Section
8.3.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_1205173] SAE Report Form.
Investigators are not obligated to activel y seek information on AEs or SAE s after the 
participant has concluded study participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the stud y, and he/she 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205174] SAE Report Form.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_1205175] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the DCT
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_1205176] requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences
.
8.3.3. Follow -Up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the cas e of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 568.3.4. Regulatory Reporting Requ irements for SAEs
Prompt notification by  [CONTACT_19990] y of participants and the safet y of a 
study  intervention under clinical investigation ar e met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requir ements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs , and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requ irements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_864314]. Such 
exposure may  or may  not lead to the occurrence of an AE or SAE. Persons at risk for 
environmental exposure include healthcare providers, famil y members, and others who may  
be exposed. An environmental exposure may  include exposure duri ng pregnancy , exposure 
during breastfeeding , and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness. 
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception. 
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP :  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by [CONTACT_78262] .

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 57A male famil y member or healthcare provider who has been exposed to the study 
intervention by [CONTACT_78263].
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information rel ated to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to 
[COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE h as occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until 28days after 
the last dose.  
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Re port Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a DCT ; however, a cop y of the 
completed CT SAE Report Form is maintained in the investigator s ite file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safe ty of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specifi ed and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and misse d abortion;
Neonatal deaths that occur within [ADDRESS_1205177] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possi bly related to 
exposure to the study  intervention. 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 58Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developm ental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An EDB occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental EDB
is a female family  member or healthcare provider who reports that she is 
breastfeeding afte r having been exposed to the study  intervention by  [CONTACT_78262] .
The investigator must report EDB to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the CT SAE 
Report Form. When exposure during breastfeeding occurs in the setting of 
environmental exposure, the exposure information does not pertain to the participant enrolled 
in the study , so the information is not recorded on a DCT . However, a copy  of the complet ed 
CT SAE Report Form is maintained in the investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding .
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 
24hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recor ded on a 
DCT ; however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file.
8.3.6.
Cardiovascular and Death Events
Not Applicable.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 598.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not Applicable.
8.3.8. Adverse Events of Special Interest
Not applicable .
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not Applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by  [CONTACT_19995], or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under study  may  occur in clinical trial settings, such as 
medication erro rs.
Safety Event Recorded on the DCT Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant.
Other examples include, but are not limited to:
Theadministration of expi[INVESTIGATOR_214312];
The administration of an incorrect study  intervention;
The administration of an incorrect dosage;

Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 60•The administration of study intervention that has undergone temperature excursion 
from the specified storage range, unless it is determined by [CONTACT_336271].
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the DCT, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within [ADDRESS_1205178] and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the DCT.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_1205179] SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics 
8.4.1. Plasma for Analysis of Abrocitinib and MetabolitesBlood samples of approximately 6 mL, to provide approximately 3 mL of plasma will be 
collected into appropriately labeled tubes containing K
2EDTA for measurement of plasma 
concentrations of abrocitinib and its metabolites PF-06471658/M1, PF-07055087/M2, and PF-07054874/M4 as specified in the 
Instructions for the collection and handling of biological samples will be provided in the 
laboratory manual or by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time (eg, within 6 minutes of a 60-minute sample) relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and data collection tool (eg, DCT). Collection of samples more than 10 hours after dose administration that are obtained ≤[ADDRESS_1205180] time of the collection is noted on the source document and data collection tool (eg, DCT). 
Plasma samples will be analyzed using validated analytical methods in compliance with 
applicable SOPs. 
 
 
CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCICCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 62 
 
 
 
 
 
 
 
 
 
8.6. Biomarkers
Biomarkers are not evaluated in this study.
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in an SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No formal inferential statistics will be applied to the safety data .CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 639.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis 
SetDescription
Enrolled All participants who sign the ICD.
Randomly assigned to 
study interventionParticipants will be randomized to [ADDRESS_1205181] they actually received.
9.3. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the 
participant populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.
9.3.1. Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, BP, pulse rate, and safety laboratory data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
 
 
 
CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, [ADDRESS_1205182] findings identified on physical examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
All safety analyses will be performed on the safety population.[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, and QRS complex will be summarized by [CONTACT_22841].
The number (%) of participants with maximum postdose QTc values and maximum increases 
from baseline in the following categories will be tabulated by [CONTACT_3148] (Table 7): 
Table 7. Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
In addition, the number of participants with uncorrected QT values >500 msec will be 
summarized.
 
 
 
 
[IP_ADDRESS]. Pharmacokinetic Analyses
[IP_ADDRESS].1. Analysis of PopulationThe PK concentration population is defined as all participants randomized and treated who 
have at least [ADDRESS_1205183] 1 treatment period.CCI
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS].2. Derivation of Pharmacokinetic Parameters Prior to Analysis
PK parameters for abrocitinib will be derived from the plasma concentrationtime profiles as 
shown in Table 8.
Table 8. Derivation of PK Parameters
Param eter Definition Method of Determ ination
AUC 24 Area under the plasma 
concentration -time profile from time 0
to 24 hoursLinear/Log trapezoidal method.
AUC last Area under the plasma 
concentration -time profile from time [ADDRESS_1205184] quantifiable 
concentration (C last)Linear/Log trapezoidal method.
AUC infaArea under the plasma 
concentration -time profile from time [ADDRESS_1205185]+ (C last*/k el),
where C last* is the predicted plasma concentration 
at the last quantifiable time point estimated from 
the log -linear regression analysis.
Cmax Maximum plasma concentration Observed directly from data.
Tmax Time for C max Observed directly from data as time of first 
occurrence.
t½aTerm inal elimination half -life Log e(2)/k el,
where k elis the terminal phase rate constant 
calculated by a linear regression of the log -linear 
concentration -time curve. Only those data points 
judged to describe the terminal log -linear decline 
will be used in the regression.
a.If data permit.
Actual PK sampling times will be used in the derivation of PK parameters.
PK parameters in Table 8 will be summarized descriptively  by [CONTACT_864315], as 
applicable, in accordance with [COMPANY_007] Data Standards. Concentrations will be listed and 
summarized descriptively b y anal yte, no minal PK sampling time and treatment. Individual 
participant and median profiles of the plasma concentration -time data will be plotted by  
[CONTACT_486832], respectively. Median profiles will be presented on 
both linear -linear and lo g-linear scales. 
For the rBA portion of Part A, natural log transformed Abrocitinib AUC inf(if data permit), 
AUC lastand C maxwill be anal yzed using a mixed effect model with sequence, period and 
treatment as fixed effects and participant within sequence as a random effect. Estimates of 
the adjusted mean differences (Test -Reference) and corresponding 90% CIswill be obtained 
from the model. The adjusted mean differences and 90% CIs
for the differences will be 
exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) 
and 90% CI s for the ratios. Treatment A (Abrocitinib tablet) is the Reference Treatment 

Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 66while Treatment B (Abrocitinib suspension) and Treatment C (Abrocitinib tablet + 
famotidine) are the Test Treatments.
For the taste assessment in Part B of the study, the data used in the analysis will be 
transcribed and rescaled to a score from 0 to 100 from the raw measurements on the questionnaire. The sensory attributes (overall liking, mouthfeel, bitterness, sourness, saltiness, tongue/mouth burn) from the taste questionnaires ( Appendix 8 ) will be listed and 
descriptively summarized by [CONTACT_864316], and question across participants. Summary statistics (mean and 90% CI) will be calculated for the various questions. Radar plots for each of [ADDRESS_1205186] unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating PK/PD modeling, and/or supporting clinical development. 
 
 
 
    
  
 
 CCI
CCI
CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 67 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 68 
 
 
10. SUPPORTING DOCUMENTS AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations10.1.1. Regulatory and Ethical ConsiderationsThis study will be conducted in accordance with the protocol and with the following:
•Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;
•Applicable ICH GCP guidelines;
•Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by [CONTACT_456], submitted to an IRB/EC by [CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to study participants.CCI
Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 69The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requir ements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Repor ting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study  participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of 
the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explai n the nature of the study, including the 
risks and benefits, to the participant and answer all questions regarding the study . The 
participant should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in th e trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection req uirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study , and possible risks 
associated wi th participation, including the risks associated with the processing of the 
participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. Th e level of disclosure must also be 
explained to the participant.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205187] be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and by  [CONTACT_90742].
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant.
Participants who are rescreened are requ ired to sign a new ICD.
10.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropri ate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site willbe responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. An y 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant -specifi c code. The study  site will 
maintain a confidential list of participants who participated in the study , linking each 
participant’s numerical code to his or her actual identity  and medical record ID. In case of 
data transfer, the sponsor will protect the co nfidentiality  of participants’ personal data 
consistent with the clinical study  agreement and applicable privacy  laws.
10.1.4. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a DMC .

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 7110.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its c ommitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulation s. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
interventional studies (conducted in participants) that evaluate the safet y and/or efficacy  of a 
product, regardless of the geographical location in which the study is conducted. These 
results are submitted for posting in accordance with the format and timelines set forth b y US 
law.
EudraCT
[COMPANY_007] posts clinical trial results on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -
sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
Pfize r complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase [ADDRESS_1205188] s, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data. Policy 0070 applies to new 
marketing authorization applications submitted via the centralized proc edure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona-fide scientific research” that contribute to the scientific understanding of the 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205189], including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assuranc e
All participant data relating to the stud y will be recorded on printed or electronic DCT unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_864317] .
Guidance on completion of DCT swill be provided in the DCT Completion Requirements 
document.
The investigator must ensure that the DCT sare securel y stored at the study site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access by [CONTACT_20011].
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, riskbased initiatives in operations and quality , such as risk management and 
mitigation strategies and anal ytical riskbased monitoring), methods, responsibilities, and 
requirements, including handling of n oncompliance issues and monitoring techniques 
(central, virtual, or onsite monitoring), are provided in the integrated quality  management 
plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data managemen t of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutiona l policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for as long as they are 
maintained.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 73When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant ’smedical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings .
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the DCT or entered in the eDCT that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
In this stud y, the DCT will serve as the source document. A document must be available at 
the investigative site that identifies those data that will be recorded on the DCT and for which 
the D CTwill be the source document.
Definition of what constitutes source data and its origin can be found in Source Document
Locator , which is maintained by  [CONTACT_456] ’s designee (CRU). Description of the use of the 
computerized sy stem is documented in Sourc e Document Locator , which is maintained by  
[CONTACT_456] ’s designee (CRU) . The investigator must maintain accurate documentation 
(source data) that supports the information entered in the DCT .
Study  monitors will perform ongoing source data verification to c onfirm that data entered 
into the DCT by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the cu rrently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants. 
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205190] been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may inclu de but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines;
Inadequate recruitment of participants by  [CONTACT_093]; 
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO(s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/o r follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be pu blished or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 y ear after the end of the study  
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications, 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments, and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] 
intervention -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the study , the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205191] editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individ ual site data. In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately  qualifi ed medical personnel for the 
study  is documented in the study  contact [CONTACT_710292] s ystem.
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact [CONTACT_74057] (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, and (c) site emergency  
phone number active 24 hou rs/day , [ADDRESS_1205192] s 
between the investigator, site staff, and study  team. The ECC is to be used by  [CONTACT_78277] y only , as a means of reaching the investigator 
or site staff related to the care of a participant. 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 7610.2. Appendix 2: Clinical Laboratory Tests
The safet y laboratory  tests listed in Table 12 will be performed at times defined in the SoA of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] ; or as derived 
from calculated values. These additional tests would not require additio nal collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess any perceived safet y concerns. 
The eGFR will be calculated using the following equation developed b y the CKD -EPI [INVESTIGATOR_864297] r:
CKD -EPI
[INVESTIGATOR_864298] ≤0.7 mg/dL:
GFR ( mL/min/1.73 m2) = 144 × (SCr/0.7)–0.329 × 0.993age(× 1.159, if black).
If female and SCr is >0.7 mg/dL:
GFR ( mL/min/1.73 m2) = 144 × (S Cr/0.7) –1.209× 0.993age(× 1.159, if black).
If male and SCr is ≤0.9 mg/dL:
GFR ( mL/min/1.73 m2) = 141 × (S Cr /0.9) –0.411× 0.993age(× 1.159, if black).
If male and SCr is >0.9 mg/dL:
GFR ( mL/min/1.73 m2) = 141 × (S Cr /0.9) –1.209× 0.993age(× 1.159, if black).

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 77Table 12. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN/urea and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
TBili
Alkaline phosphatase
Uric acid
Albumin
Total protein
eGFR based on the 
CKD -EPI [INVESTIGATOR_864299] (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaCOVID -19 testing
Urine drug screeningb
Pregnancy testc
At screening only:
FSHd
HBsAg
HBcAb
HBsAbe
HCVAb
HIV
QuantiFERON®-TB 
Gold Test
Additional Tests 
(Needed for Hy’s Law)
AST, ALT (repeat)
TBili (repeat)
Albumin (repeat)
Alkaline phosphatase 
(repeat)
Direct bilirubin
Indirect bilirubin
CK
GGT
PT/INR
Total bile acids
Acetaminophen drug 
and/or protein adduct 
levels
a.Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
b.The minimum requirement for drug screening includes cocaine, tetrahydrocannabinol, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site specific).
c.Pregnancy test for female participants of chi ldbearing potential.
d.For confirmation of postmenopausal status only ( only females who are amenorrheic for at least 
12consecutive months ).
e.HBsAb tested as reflex test only in participants who are HBsAg negative, but are HBcAb positive.
The investigator mu st review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the DCT .

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 78Any remaining serum from samples collected for clinical safet y laboratory measurements at 
baseline and at all times after dose administration may  be retained and stored for the duration 
of the study . Upon completion of the study , these retained safet y samples may be used for the 
assessment of exploratory  safet y biomarkers or une xpected safet y findings. These data will 
not be included in the CSR. Samples to be used for this purpose will be shipped to either a 
[COMPANY_007] -approved BBS facility  or other designated laboratory  and retained for up to 1 year 
following the completion of the s tudy.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 7910.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study  intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator .Any abnormal laboratory test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated wi th accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/ SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 80Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to t he procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose , meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event that 
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate i n the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.
d.Results in persistent or significant disability/incapacity

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 81The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] prod uct of an infectious agent, pathogenic 
or non- pathogenic, is considered serious.  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmiss ion” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_78278], such as significant
medical events that may jeopardize the participant or may  require medical or 
surgi cal intervention to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the DCT and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form fo r reporting of SAE information is not 
the same as the AE page of the DCT . When the same data are collected, the forms must be 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205193] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, All AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note:  I nstances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the DCT .All instances of EDP are 
reported (whether or not 
there is an associated SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure to 
the product under stud y 
to a non -participant (not 
involving EDP or EDB).None.  Exposure to a study  
non-participant is not 
collected on the DCT .The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report 
Form. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form. 
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the DCT .

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 83It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form/AE orSAE DCT page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety. In this case, all participant identifiers, with the 
exception of the participant number, wi ll be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money , etc.
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospi[INVESTIGATOR_3111]; disabling, limiting self 
care ADL. Self c are ADL refers to bathing, dressing and undressing, feeding self, 
using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT wh en it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE. The investigator will use clinical judgment 
to determine the relationship.
A “reasonable possibility” of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 84Alternative causes, such as underl ying disease(s), concomitant therap y, an d other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assess ment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined b y the sponsor. In addition, if the investigator determines that 
an SAE is associated wit h study  procedures, the investigator must record this 
causal relationship in the source documents and DCT , and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare professionals.
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology . 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 85New or updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 8610.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
No contraception methods are required for male participants in this study , as the calculated 
safet y margin is ≥100-fold between the estimated maternal exposure due to seminal transfer 
and the no
-observed-adverse- effect level for serious manifestations of developmental toxicity  
in nonclinical studies.
10.4.2. Female Participant Reproductive Inclusion Criteria
A female parti cipant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure 
rate of <1% per 
year), as described below, during the intervention period and for at 
least [ADDRESS_1205194] dose of study  intervention, which corresponds to the time 
needed to eliminate an y reproductive safet y risk of the study intervention(s). If a 
highl y effective method that is user dependent is chosen, a second effective method of 
contraception, as described below, must also be used. The inv estigator should 
evaluate the effectiveness of the contraceptive method in relationship to the first dose 
of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential 
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additiona l evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 87Documented bilateral oophorectom y.
For individuals wit h permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female.
A postme nopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition:
A high FSH level in the postmenopausal range mustbe used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study . Otherwise, they  must 
discontinue HRT t o allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contraception Methods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in cl inical trials.
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner.
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the woman of childbearing potential and 
the absence of sperm has been confirmed. If not, an additional highl y effective 
method of contra ception should be used. The spermatogenesis cy cle is 
approximately  90days.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 886.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation.
Oral;
Intravaginal;
Transdermal;
Injectable.
7.Progestogen -only hormon e contraception associated with inhibition of ovulation.
Oral;
Injectable.
8.Sexual abstinence.
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
In addition, one of the following effective barrier methods must also be used when 
option 6 or 7 are chosen above:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 8910.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRBs/ECs allow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  be narrow (eg, 1 or more candidate genes) or 
broad (eg, the entire genome), as appropriate to the scientific question under 
investigation.
The samples may  be an alyzed as part of a multistudy  assessment of genetic factors 
involved in the response to study  intervention or study  interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic an alyses may  be reported in the CSR or in a separate study  
summary  ormay be used for internal decision making without being included in a 
study  report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confid entiality . 
The samples will be retained as indicated:
Samples for specified genetic anal ysis (see Section 8.5.1) will be stored for a 
period of up to 3 years after regulatory  approval.
Retained samples (see Section 8.5.2) will be stored indefinitely  or for another
period as per local requirements.
Participants may  withdraw their consent for the storage and/or use of their Retained 
Research Samples at an y tim
e by [CONTACT_7328] a request to the investigator; in this case, 
any remaining material will be destroy ed. Data already  generated from the samples 
will be retained to protect the integrit y of existing anal yses.
Samples for genetic research will be labeled with a code. The key  between the code 
and the participant’s personally  identify ing information (eg, name, address) will be 
held securely at the study site. 

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 9010.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors”. In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participants who experience a transamina se elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations (>2 ×
ULN) b y several days or weeks. The increa se in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are 
still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within the same 
laboratory  sample). In rare instances, by  [CONTACT_22858], AST/ALT 
values might have decrea sed. This occurrence is still regarded as a potential DILI. Therefore, 
abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria 
outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases and 
should alway s be considered important medical events, even before all other possible causes 
of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying c onditions. Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smalle r).

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205195]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
Theparticipant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_1205196] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT , PT/I NR, total bile acids, and alkaline phosphatase. Consideration should al so 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology . A detailed history , including relevant information, 
such as review of ethanol, 
acetaminophen (either by [CONTACT_20025] a coformulated product in 
prescription or over -the-counter medications), recreational drug, supplement (herbal) use and 
consumption, family  history , sexual history , travel history , history  of contact [CONTACT_4490] a 
jaundiced person, surgery, blood transfusion, history  of liver or allergic disease, and potential 
occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, 
B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of serum sample 
for acetaminophen drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevatio n defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 9210.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus brady cardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec (absolute) or by≥60msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate <120 bpm.
New -onset ty peI second -degree (Wenckebach) AV block of >30 seconds’ 
duration.
Frequent premature ventricular complexes ,triplets, or short intervals 
(<30 seconds) of consecutive ventricular complexes.
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 msec.
New ST -Tchanges suggestive of myocardial ischemia.
New -onset left bundle branch block (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec).
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom -free participants in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhythm 
that is below the AV node. 
In awake, s ymptom -free participants with atrial fibrillation and brady cardia 
with [ADDRESS_1205197] 5 seconds or longer. 
Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular ta chycardia (rate >120 bpm) (“sustained” = short 
duration with relevant s ymptoms or lasting >1 minute).

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 93Ventricular rh ythms >30 seconds’ duration, including idioventricular rhy thm (heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR >40 bpm to <100 b pm), and 
monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as 
torsades de pointes)).
Type II second -degree (Mobitz II) AV block.
Complete (third- degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction. 
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fi brillation with rapid ventricular response requiring cardioversion.
Ventricular fibrillation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and [COMPANY_007] study team, and not to be 
considered as all-inclusive of what to be reported as AEs/S AEs.

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 9410.8. Appendix 8: Taste Assessment Questionnaire
1.
Questionnaire should be administered to adult participants, preferabl yby[CONTACT_864318]. The clinical staff is trained by  [CONTACT_864319].
2.Use colored cop yof the questionnaire.
3.Do not alter (reduce or enlarge) the original size of the questionnaire.
4.
Please gather the following background information: 
Background Information
Study  #/Study  Site
Period and Day
Participant ID (Rand ID)
Formulation ID
Collection Date
Collection Time
Name [CONTACT_864321] y completed Yes/No

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 95Example: How to provide a mark ( Ï ) on the color bar

Good (score = 0)
Bad (score = 100)

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 96

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 97

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 98

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 99

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 100

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 101

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 102

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
 ongoing/continuous event
Abs absolute
AD atopic dermatitis
AE adverse event
AIA adjuvant -induced arthritis
ALT alanine aminotransferase
ARA acid-reducing agent
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the curve
AUC [ADDRESS_1205198] cancer resistance protein
BID twice dail y
BLQ below the limit of quantification
BMI body  mass index
BP blood pressure
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_273472]/F apparent clearance
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_1205199] clinical trial

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May [ADDRESS_1205200] gastroesophageal reflux disease
GFR glomerular filtration rate
GGT gamma -glutamy l transferase
GLP Good Laboratory  Practice
H2 histamine -2
HBcAb hepatitis B core antibod y
HBsAb hepatitis B surface antibody  
HBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HDPE High Density  Poly Ethylene
hERG human ether -á-go-go-related gene
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB investigator’s brochure
IC50 50% inhibitory  concentration
ICD informed consent document
ICH International Council for Harmonisation
ID identity

Abrocitinib (PF-04965842)
B7451061Final Protocol, [ADDRESS_1205201] medical device regulation
mRNA message ribonucleic acid
N/A not applicable
NADPH nicotinamide adenine dinucleotide phosphate
NOAEL no-observed-adverse-effect level
OAT organic anion transporter
OATP for organic anion transporting polypeptide
OCT organic cation transporte r
PBMC peripheral blood mononuclear cells
PCR Polymerase Chain Reaction
PCRU [COMPANY_007] Clinical Research Unit
PD pharmacodynamic(s)
PEER Pediatric Eczema Elective Registry
P-gp P-glycoprotein
pH negative logarithm of hydrogen ion concentration
PI [INVESTIGATOR_19959](s)
POC proof-of-concept
PPI [INVESTIGATOR_864300] (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page 106Abbreviation Term
QD once dail y
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
Rac accumulation ratio
rBA relative BA
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analy sis plan
SARS severe acute respi[INVESTIGATOR_864301] p yruvic transaminase
SoA schedule of activities
SOC System Organ Class
SOP standard operating procedure
SRSD single reference safet y document
STAT signal transducers and activators of transcription
SUL T sulfotransferase
S[LOCATION_003]R suspected unexpected serious adverse reaction
t½ apparent terminal half -life
TB tuberculosis
TBili total bilirubin
TEAE treatment emergent AE
Tmax time to maximum concentration
TSLP thymic stromal lymphopoietin
TYK tyrosine kinase
UGT uridine diphospho -glucuronosy ltransferase
ULN upper limit of normal
US [LOCATION_002]
Vc/F apparent central volume of distribution
VEGFR vascular endothelial growth factor receptor
Vp/F apparent peripheral volume of distribution
WBC white blood cell
WOCBP woman /women of childbearing potential

Abrocitinib (PF-04965842)
B7451061
Final Protocol , 06May 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].REFERENCES
1Investigator’s Brochure, Abrocitinib (PF- 04965842). Apr 2020.
2Murray  PJ. The JAK -STAT signaling pathway : input and output integration. J I mmunol .
2007;78(5):2623 -9.
3O’Sullivan L A, Liongue C, L ewis RS, et al. C ytokine receptor signaling through the 
Jak-Stat-Socs pathway  in disease. Mol Immunol 2007;44(10):2497 -506.
4Auriemma M, Vianale G, Amerio P, et al. Cytokines and T cells in atopic dermatitis. 
Eur Cy tokine Netw . 2013;24(1):37-44.
5Eichenfield LF, Ellis CN, Mancini AJ, et al. Atopic dermatitis: epi[INVESTIGATOR_74042]. Semin Cutan Med Surg
.2012;31:S3 -5.
6Leicht S, Hanggi M. Atopic dermatitis. How to incorporate advances in management. 
Postgrad Med .2001;109(6):119 -27.
7Margolis JS, Abuabara K, Bilker W, et al. Persistence of mild to moderate atopic 
dermatitis. JAMA Dermatol. 2014;150(6):593 -600.
8Slater NA, Morrell DS. Sy stemic therapy  of childhood atopic dermatitis. Clin Dermatol .
2015;33(3):289 -99.
9Leung DY, Bieber T. Atopic dermatitis. Lancet .2003;361(9352):151-60.
10Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic 
dermatitis) part I. J Eur Acad Dermatol Venereol .2012;26(8):1045 -60.
11US Food and Drug Admi nistration. Guidance for industry :bioavailability  studies 
submitted in NDAs or INDs — general considerations. Rockville, MD: Center for Drug 
Evaluation and Research; Feb 2019.
12Miner PB Jr, Allgood LD, Grender JM. Comparison of gastric pH with omeprazole
magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and 
famotidine 20 mg b.d. over 14 day s of treatment. Aliment Pharmacol Ther .
2007;25(1):103 -9.
13Abe Y, Inamori M, Togawa J, et al. The comparative effects of single intravenous doses
of omeprazole and famotidine on intragastric pH. J Gastroenterol 2004 Jan;39(1):21 -5.                                                

Abrocitinib (PF-04965842)
B7451061Final Protocol, 06 May 2021
PFIZER CONFIDENTIAL
Page 10814PEPCID® (famotidine) [prescribing information]. Bridgewater, NJ: Valeant 
Pharmaceuticals North America LLC; 2018.
15Kent JD, Holt RJ, Jung D, et al. Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysis. J Drug Assess 2014 Feb;17;3(1):20-7.
16US Food and Drug Administration. Guidance for industry: evaluation of gastric pH-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications. Rockville, MD: Center for Drug Evaluation and Research; Nov 2020.
 
 
 
19US Food and Drug Administration. S3A Guidance: Note for Guidance on toxicokinetics: The assessment of systemic exposure in toxicity studies: focus on microsampling questions and answers guidance for industry. Published: May 2018. Accessed: [ADDRESS_1205202] 2020.
20Land O’Lakes Workshop on Microsampling: enabling broader adoption. Th AAPS Journal, published online: 23 October 2020.C
CI